BR122021026173B1 - Composição farmacêutica - Google Patents

Composição farmacêutica Download PDF

Info

Publication number
BR122021026173B1
BR122021026173B1 BR122021026173-3A BR122021026173A BR122021026173B1 BR 122021026173 B1 BR122021026173 B1 BR 122021026173B1 BR 122021026173 A BR122021026173 A BR 122021026173A BR 122021026173 B1 BR122021026173 B1 BR 122021026173B1
Authority
BR
Brazil
Prior art keywords
cells
cell
antigen
seq
car
Prior art date
Application number
BR122021026173-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Carl H. June
Bruce L. Levine
David L. Porter
Michael D. Kalos
Michael C. Milone
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR122021026173(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of BR122021026173B1 publication Critical patent/BR122021026173B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR122021026173-3A 2010-12-09 2011-12-09 Composição farmacêutica BR122021026173B1 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US42147010P 2010-12-09 2010-12-09
US61/421,470 2010-12-09
US201161502649P 2011-06-29 2011-06-29
US61/502,649 2011-06-29
PCT/US2011/064191 WO2012079000A1 (en) 2010-12-09 2011-12-09 Use of chimeric antigen receptor-modified t cells to treat cancer
BR112013014265A BR112013014265B8 (pt) 2010-12-09 2011-12-09 Molécula de ácido nucleico isolada, receptor antígeno quimérico isolado, e, vetor

Publications (1)

Publication Number Publication Date
BR122021026173B1 true BR122021026173B1 (pt) 2023-12-05

Family

ID=46207528

Family Applications (3)

Application Number Title Priority Date Filing Date
BR122021026173-3A BR122021026173B1 (pt) 2010-12-09 2011-12-09 Composição farmacêutica
BR122021026169-5A BR122021026169B1 (pt) 2010-12-09 2011-12-09 Uso de uma célula
BR112013014265A BR112013014265B8 (pt) 2010-12-09 2011-12-09 Molécula de ácido nucleico isolada, receptor antígeno quimérico isolado, e, vetor

Family Applications After (2)

Application Number Title Priority Date Filing Date
BR122021026169-5A BR122021026169B1 (pt) 2010-12-09 2011-12-09 Uso de uma célula
BR112013014265A BR112013014265B8 (pt) 2010-12-09 2011-12-09 Molécula de ácido nucleico isolada, receptor antígeno quimérico isolado, e, vetor

Country Status (43)

Country Link
US (15) US9499629B2 (enExample)
EP (4) EP3660029A1 (enExample)
JP (7) JP5947311B2 (enExample)
KR (5) KR102062407B1 (enExample)
CN (5) CN107699585A (enExample)
AP (1) AP2013006918A0 (enExample)
AU (5) AU2011338200B2 (enExample)
BR (3) BR122021026173B1 (enExample)
CA (1) CA2820681C (enExample)
CL (1) CL2013001645A1 (enExample)
CO (1) CO6801633A2 (enExample)
CR (1) CR20130269A (enExample)
CY (3) CY1119760T1 (enExample)
DK (2) DK2649086T3 (enExample)
DO (1) DOP2013000128A (enExample)
EA (2) EA027153B1 (enExample)
EC (1) ECSP13012739A (enExample)
ES (2) ES2641870T3 (enExample)
FR (1) FR19C1006I2 (enExample)
GT (1) GT201300150A (enExample)
HK (2) HK1243082B (enExample)
HR (2) HRP20171577T1 (enExample)
HU (4) HUE042207T2 (enExample)
IL (1) IL226694B (enExample)
LT (4) LT3214091T (enExample)
LU (1) LUC00104I2 (enExample)
MA (1) MA34813B1 (enExample)
MX (3) MX347078B (enExample)
MY (2) MY191313A (enExample)
NI (1) NI201300051A (enExample)
NL (1) NL300967I2 (enExample)
NO (2) NO2019007I1 (enExample)
NZ (1) NZ612512A (enExample)
PE (1) PE20140178A1 (enExample)
PH (1) PH12013501201A1 (enExample)
PL (2) PL3214091T3 (enExample)
PT (2) PT3214091T (enExample)
RS (2) RS56453B1 (enExample)
SG (2) SG190997A1 (enExample)
SI (2) SI3214091T1 (enExample)
TR (1) TR201820015T4 (enExample)
WO (1) WO2012079000A1 (enExample)
ZA (1) ZA201304470B (enExample)

Families Citing this family (1351)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2557164A1 (en) 2003-02-18 2013-02-13 Kevin M. Slawin Induced activation in dendritic cells
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8871211B2 (en) 2006-09-28 2014-10-28 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
DK2279253T3 (en) 2008-04-09 2017-02-13 Maxcyte Inc Construction and application of therapeutic compositions of freshly isolated cells
WO2010028066A2 (en) 2008-09-02 2010-03-11 Cedars-Sinai Medical Center Cd133 epitopes
US8415150B2 (en) * 2009-02-24 2013-04-09 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (PML)
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
US20130302276A1 (en) 2010-10-22 2013-11-14 Dana-Farber Cancer Insitute Inc., Discovery of regulatory t cells programmed to suppress an immune response
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
AU2012242847B2 (en) 2011-04-15 2017-01-19 The Johns Hopkins University Safe sequencing system
US9868774B2 (en) * 2011-10-20 2018-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD22 chimeric antigen receptors
WO2013063419A2 (en) * 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
SG11201404284SA (en) 2012-02-22 2014-10-30 Univ Pennsylvania Use of the cd2 signaling domain in second-generation chimeric antigen receptors
KR20140127816A (ko) 2012-02-22 2014-11-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
ES2812849T3 (es) 2012-02-24 2021-03-18 Abbvie Stemcentrx Llc Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
CA3116051C (en) * 2012-03-23 2023-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
MX394639B (es) 2012-04-11 2025-03-24 Us Health Receptores del antigeno quimerico que seleccionan el antigeno para la maduracion de las celulas b
DK3473707T3 (da) 2012-05-25 2025-03-17 Cellectis Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
AU2013289970A1 (en) * 2012-07-13 2015-01-22 The Trustees Of The University Of Pennsylvania Compositions and methods for regulating CAR T cells
JP2015524255A (ja) 2012-07-13 2015-08-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
WO2014011996A1 (en) * 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Methods of assessing the suitability of transduced t cells for administration
WO2014011993A2 (en) * 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Epitope spreading associated with car t-cells
BR112015000657B1 (pt) * 2012-07-13 2023-12-05 The Trustees Of The University Of Pennsylvania Uso de uma célula geneticamente modificada para expressar um car
KR102204029B1 (ko) 2012-07-13 2021-01-19 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｃａｒ의 항-종양 활성에 대한 독성 관리
IL293944A (en) * 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
WO2014039523A1 (en) * 2012-09-04 2014-03-13 Cellectis Multi-chain chimeric antigen receptor and uses thereof
US9416190B2 (en) * 2012-09-27 2016-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
WO2014052545A2 (en) 2012-09-28 2014-04-03 Dana-Farber Cancer Institute, Inc. Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis
US9365641B2 (en) * 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
ES2718903T3 (es) * 2012-10-24 2019-07-05 Us Health Receptores de antígenos quiméricos M971
EP2912468B1 (en) 2012-10-29 2018-09-12 The Johns Hopkins University Papanicolaou test for ovarian and endometrial cancers
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
AU2015210373B2 (en) * 2012-12-20 2017-04-06 Celgene Corporation Chimeric antigen receptors
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
NZ711807A (en) * 2013-02-06 2020-06-26 Celgene Corp Modified t lymphocytes having improved specificity
EP2956544B1 (en) 2013-02-14 2017-11-01 Immunocellular Therapeutics Ltd. Cancer vaccines and vaccination methods
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
CN111139256A (zh) * 2013-02-20 2020-05-12 诺华股份有限公司 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
MY175869A (en) 2013-02-26 2020-07-14 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
EP2964675B1 (en) * 2013-03-05 2018-06-20 Baylor College Of Medicine Engager cells for immunotherapy
WO2014153114A1 (en) 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US9587237B2 (en) 2013-03-14 2017-03-07 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
WO2014151960A2 (en) * 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
US9499855B2 (en) * 2013-03-14 2016-11-22 Elwha Llc Compositions, methods, and computer systems related to making and administering modified T cells
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
CN105264127B (zh) 2013-03-15 2019-04-09 Gpb科学有限责任公司 颗粒的片上微流体处理
US9745368B2 (en) 2013-03-15 2017-08-29 The Trustees Of The University Of Pennsylvania Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN105247042B (zh) 2013-03-15 2021-06-11 普林斯顿大学理事会 用于高通量纯化的方法和设备
IL311390A (en) 2013-03-15 2024-05-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
CA2907397C (en) 2013-03-15 2022-11-22 Anthrogenesis Corporation Modified t lymphocytes
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
AU2014259675B2 (en) 2013-05-03 2019-05-02 Ohio State Innovation Foundation CS1-specific chimeric antigen receptor engineered immune effector cells
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
US11311575B2 (en) * 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
SI3546572T1 (sl) * 2013-05-13 2024-06-28 Cellectis CD19 specifični himerni antigenski receptor in njegova uporaba
ES2828982T3 (es) 2013-05-14 2021-05-28 Univ Texas Aplicación humana de células t de receptor de antígeno quimérico (car) diseñadas
WO2014190273A1 (en) * 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
ES2897579T3 (es) 2013-06-10 2022-03-01 Dana Farber Cancer Inst Inc Métodos y composiciones para reducir la inmunosupresión por células tumorales
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
US9808486B2 (en) 2013-08-30 2017-11-07 Board Of Regents, The University Of Texas System Administration of kynurenine depleting enzymes for tumor therapy
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
CN105813654B (zh) 2013-10-11 2019-05-31 美国政府(由卫生和人类服务部的部长所代表) Tem8抗体及其用途
KR102357968B1 (ko) * 2013-10-15 2022-02-03 더 스크립스 리서치 인스티튜트 키메라 항원 수용체 t 세포 스위치 및 이의 용도
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
SG11201602979RA (en) * 2013-10-17 2016-05-30 Univ Singapore Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
CN104561069A (zh) * 2013-10-23 2015-04-29 深圳先进技术研究院 含重组嵌合抗原受体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
US20150140036A1 (en) * 2013-11-13 2015-05-21 Novartis Institutes For Biomedical Research, Inc. Low, immune enhancing, dose mtor inhibitors and uses thereof
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015077789A2 (en) 2013-11-25 2015-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control hiv infection
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US10676528B2 (en) 2013-12-06 2020-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
US10640569B2 (en) * 2013-12-19 2020-05-05 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP4420663A3 (en) 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
AU2014368383B2 (en) * 2013-12-20 2020-01-16 Cellectis Method of engineering multi-input signal sensitive T cell for immunotherapy
MX386422B (es) 2013-12-20 2025-03-18 Fred Hutchinson Cancer Center Moléculas efectoras químericas etiquetadas y receptores de las mismas.
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
ES2767423T3 (es) * 2014-01-13 2020-06-17 Hope City Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso
ES2963718T3 (es) 2014-01-21 2024-04-01 Novartis Ag Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015120363A1 (en) * 2014-02-10 2015-08-13 Emory University Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
MX375123B (es) 2014-02-14 2025-03-06 Immune Design Corp Composición para usarse en mejorar la respuesta inmune contra el cáncer.
CA2937750A1 (en) * 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
EP3105317B1 (en) * 2014-02-14 2018-09-19 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
CA3190002A1 (en) * 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
CA2939711C (en) * 2014-02-21 2020-09-29 Cellectis Method for in situ inhibition of regulatory t cells
CN103820393B (zh) * 2014-02-24 2016-09-07 西比曼生物科技（上海）有限公司 工程化cd20靶向性的nkt细胞及其制备方法和应用
CA2939305A1 (en) 2014-02-27 2015-09-03 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
CN104877028A (zh) * 2014-02-28 2015-09-02 百奥迈科生物技术有限公司 抗dota嵌合抗原受体修饰的t细胞及其抗肿瘤的应用
EP3125934B1 (en) * 2014-03-05 2019-10-23 UCL Business Plc. Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US20230027993A1 (en) 2014-03-05 2023-01-26 Autolus Limited Methods
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
EP3660050A1 (en) 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
MX370272B (es) 2014-03-19 2019-12-09 Cellectis Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
WO2015143224A1 (en) * 2014-03-19 2015-09-24 Ambrx, Inc. Chimeric antigen receptor-modified t-cells
CA2942101A1 (en) 2014-03-21 2015-09-24 Abbvie Inc. Anti-egfr antibodies and antibody drug conjugates
CA2944528C (en) * 2014-04-03 2021-08-10 Cellectis Cd33 specific chimeric antigen receptors for cancer immunotherapy
SG11201608389RA (en) 2014-04-07 2016-11-29 Minerva Biotechnologies Corp Anti-nme antibody
LT3129470T (lt) * 2014-04-07 2021-07-12 Novartis Ag Vėžio gydymas naudojant anti-cd19 chimerinį antigeno receptorių
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
CA2945620C (en) * 2014-04-14 2022-12-06 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
AU2015249554B2 (en) 2014-04-23 2021-08-19 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
US20170049819A1 (en) * 2014-04-25 2017-02-23 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
SMT202100700T1 (it) 2014-04-25 2022-01-10 2Seventy Bio Inc Recettori antigenici chimerici con promotore mnd
SG11201608744VA (en) 2014-04-25 2016-11-29 Bluebird Bio Inc Improved methods for manufacturing adoptive cell therapies
US10494422B2 (en) * 2014-04-29 2019-12-03 Seattle Children's Hospital CCR5 disruption of cells expressing anti-HIV chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
CN107074929B (zh) 2014-05-02 2021-09-03 宾夕法尼亚大学董事会 嵌合自身抗体受体t细胞的组合物和方法
JP2017514522A (ja) 2014-05-02 2017-06-08 エモリー ユニバーシティー ヒト化可変性リンパ球受容体（ｖｌｒ）および組成物ならびにそれに関連する使用
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
CA2947290A1 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
KR20200000495A (ko) 2014-05-14 2020-01-02 카르스젠 테라퓨틱스 리미티드 키메라 항원 수용체 단백질을 코딩하는 핵산 및 키메라 항원 수용체 단백질을 발현하는 t 림프구
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
US11041021B2 (en) 2014-05-23 2021-06-22 University Of Florida Research Foundation, Incorporated Car based immunotherapy
EP3149044B1 (en) 2014-06-02 2020-10-21 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chimeric antigen receptors targeting cd-19
EP3151672B1 (en) 2014-06-06 2020-11-04 Bluebird Bio, Inc. Improved t cell compositions
AU2015276131A1 (en) * 2014-06-17 2016-11-17 Cellectis CD123 specific multi-chain chimeric antigen receptor
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
MX2017000646A (es) 2014-07-15 2017-04-27 Juno Therapeutics Inc Celulas geneticamente modificadas para terapia celular adoptiva.
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
CN107109420A (zh) * 2014-07-21 2017-08-29 诺华股份有限公司 使用cll－1嵌合抗原受体的癌症治疗
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
KR102523934B1 (ko) 2014-07-24 2023-04-20 2세븐티 바이오, 인코포레이티드 Bcma 키메릭 항원 수용체
EP3453406B1 (en) * 2014-07-29 2021-04-14 Cellectis Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy
CA2956307A1 (en) * 2014-07-29 2016-02-04 Pfizer Inc. Egfrviii specific chimeric antigen receptors for cancer immunotherapy
US10544201B2 (en) 2014-07-31 2020-01-28 Cellectis ROR1 specific multi-chain chimeric antigen receptor
EP3660042B1 (en) 2014-07-31 2023-01-11 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
AU2015305531B2 (en) 2014-08-19 2021-05-20 Novartis Ag Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment
CA2957958C (en) 2014-08-27 2023-10-17 Harvey Cantor Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
EP2990416B1 (en) * 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
IL250833B (en) 2014-08-29 2022-09-01 Univ Texas Administration of kynurenine depleting enzymes for tumor therapy
CA2959168A1 (en) 2014-09-02 2016-03-10 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
WO2016034666A1 (en) * 2014-09-04 2016-03-10 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
MX2017003062A (es) * 2014-09-09 2017-12-14 Unum Therapeutics Receptores quimericos y usos de los mismos en terapia inmune.
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
ES2875057T3 (es) 2014-09-17 2021-11-08 Us Health Anticuerpos anti-CD276 (B7H3)
RU2749922C2 (ru) * 2014-09-19 2021-06-21 Сити Оф Хоуп Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2
WO2016054153A1 (en) * 2014-10-02 2016-04-07 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
JP2017531430A (ja) * 2014-10-07 2017-10-26 セレクティスＣｅｌｌｅｃｔｉｓ Ｃａｒによって誘導される免疫細胞の活性を調節するための方法
CN114107424A (zh) 2014-10-08 2022-03-01 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
HUE046710T2 (hu) * 2014-10-09 2020-03-30 Univ Yamaguchi CAR expressziós vektor és CAR-t expresszáló T-sejtek
KR102122463B1 (ko) 2014-10-14 2020-06-15 할로자임, 아이엔씨 아데노신 디아미네이즈-2(ada2)의 조성물, 이의 변이체 및 이를 사용하는 방법
MX392487B (es) * 2014-10-20 2025-03-21 Juno Therapeutics Inc Métodos y composiciones para dosificación en terapia celular adoptiva.
RU2708459C2 (ru) 2014-10-29 2019-12-09 БайсиклРД Лимитед Бициклические пептидные лиганды, специфичные для мт1-ммр
AU2015339743C1 (en) 2014-10-31 2021-04-22 The Trustees Of The University Of Pennsylvania Altering gene expression in modified T cells and uses thereof
CN107106609A (zh) * 2014-10-31 2017-08-29 宾夕法尼亚大学董事会 刺激和扩展t细胞的组合物和方法
WO2016073748A1 (en) * 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Biomarkers and targets for cancer immunotherapy
EP3215534B1 (en) 2014-11-05 2020-04-15 Board of Regents, The University of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
JP2017535284A (ja) 2014-11-05 2017-11-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫エフェクター細胞の拡大のための遺伝子改変免疫エフェクター細胞及び遺伝子操作細胞
WO2016073602A2 (en) 2014-11-05 2016-05-12 Juno Therapeutics, Inc. Methods for transduction and cell processing
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
SI3218005T1 (sl) * 2014-11-12 2023-06-30 Seagen Inc. Z glikanom delujoče spojine, in postopki uporabe
CN105601746B (zh) * 2014-11-21 2021-02-19 三生国健药业（上海）股份有限公司 一种嵌合Fc受体的融合蛋白及其制备方法和应用
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
KR102804498B1 (ko) * 2014-12-03 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 치료를 위한 방법 및 조성물
JP6753851B2 (ja) 2014-12-05 2020-09-09 メモリアル スローン ケタリング キャンサー センター Ｇタンパク質共役受容体を標的化する抗体および使用の方法
ES2966099T3 (es) * 2014-12-05 2024-04-18 Memorial Sloan Kettering Cancer Center Receptores de antígeno quiméricos dirigidos al antígeno de maduración de células B y usos de los mismos
HUE053995T2 (hu) 2014-12-05 2021-08-30 Memorial Sloan Kettering Cancer Center B-sejt-érési antigént célzó antitestek és alkalmazási eljárások
ES2899779T3 (es) 2014-12-05 2022-03-14 Memorial Sloan Kettering Cancer Center Receptores antigénicos quiméricos dirigidos a receptor acoplado a proteína G y usos de los mismos
AU2015357485B2 (en) 2014-12-05 2020-10-15 City Of Hope CS1 targeted chimeric antigen receptor-modified T cells
ES2921208T3 (es) * 2014-12-08 2022-08-19 Us Health Receptores de antígeno quimérico anti-CD70
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
CA2970466A1 (en) 2014-12-12 2016-06-16 Bluebird Bio, Inc. Bcma chimeric antigen receptors
SI3240805T1 (sl) 2014-12-15 2025-04-30 The Regents Of The University Of California Bispecifični or-gate himerni antigenski receptor, odziv na cd19 in cd20
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
CN114107212A (zh) * 2014-12-24 2022-03-01 奥托路斯有限公司 细胞
CA2972597A1 (en) * 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
AR103442A1 (es) 2015-01-16 2017-05-10 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos de ror1
AU2016212158B2 (en) 2015-01-26 2021-06-03 Allogene Therapeutics, Inc. mAb-driven chimeric antigen receptor systems for sorting/depleting engineered immune cells
ES3007649T3 (en) * 2015-01-29 2025-03-20 Univ Minnesota Chimeric antigen receptors, compositions, and methods
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
JP6895380B2 (ja) 2015-02-06 2021-06-30 ナショナル ユニバーシティ オブ シンガポール 治療免疫細胞の有効性を改良するための方法
AU2016219511B2 (en) 2015-02-09 2020-11-12 Research Development Foundation Engineered immunoglobulin Fc polypeptides displaying improved complement activation
US20160228544A1 (en) * 2015-02-11 2016-08-11 Ensysce Biosciences, Inc. Single Walled Carbon Nanotube Polynucleotide Complexes and Methods Related Thereto
US11248058B2 (en) * 2015-02-19 2022-02-15 University Of Florida Research Foundation, Inc. Chimeric antigen receptors and uses thereof
US10973914B2 (en) 2015-02-20 2021-04-13 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
WO2016138034A1 (en) 2015-02-24 2016-09-01 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
CN107667169B (zh) 2015-02-24 2021-10-29 得克萨斯州大学系统董事会 遗传修饰的t细胞的选择方法
CA2977106A1 (en) 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
US10195272B2 (en) 2015-03-02 2019-02-05 The Nemours Foundation Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
EP3549612B1 (en) * 2015-03-02 2025-04-30 Innovative Cellular Therapeutics Holdings, Ltd. Reducing immune tolerance induced by pd-l1
US20180044404A1 (en) * 2015-03-05 2018-02-15 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
JP2018513123A (ja) 2015-03-12 2018-05-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｏｒガンマ阻害剤を用いてがんを治療するための方法
CN107708710A (zh) * 2015-03-17 2018-02-16 嵌合体生物工程公司 Smart CAR装置,DE CAR多肽,Side CAR及其使用
WO2016149578A1 (en) 2015-03-19 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
HRP20200583T1 (hr) 2015-03-20 2020-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protutijela koja neutraliziraju gp120 i njihova upotreba
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
US11136401B2 (en) 2015-03-27 2021-10-05 University Of Southern California Car t-cell therapy directed to LHR for the treatment of solid tumors
WO2016160622A2 (en) * 2015-03-27 2016-10-06 University Of Southern California Hla-g as a novel target for car t-cell immunotherapy
WO2016161415A2 (en) * 2015-04-02 2016-10-06 Memorial Sloan Kettering Cancer Center Tnfrsf14/ hvem proteins and methods of use thereof
HK1249048A1 (zh) 2015-04-03 2018-10-26 Eureka Therapeutics, Inc. 靶向afp肽/mhc复合体的构建体及其用途
KR102788389B1 (ko) 2015-04-06 2025-03-31 서브도메인, 엘엘씨 드 노보 결합 도메인 함유 폴리펩티드 및 그의 용도
JP6879932B2 (ja) 2015-04-06 2021-06-02 サイトイミューン セラピューティクス， インコーポレイテッドＣｙｔｏｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ 神経膠芽腫のためのｅｇｆｒ指向ｃａｒ療法
HRP20220893T1 (hr) * 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
WO2016168773A2 (en) 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
EP3283619B1 (en) 2015-04-17 2023-04-05 Novartis AG Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN108136021A (zh) 2015-04-25 2018-06-08 综合医院公司 用于治疗癌症的抗驱走性试剂和抗癌剂联合疗法和组合物
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
WO2016176651A2 (en) * 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3288568A4 (en) * 2015-04-30 2019-01-02 University of Southern California Secretory tnt car cell immunotherapy
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
WO2016174652A1 (en) * 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
HK1250569A1 (zh) 2015-05-01 2018-12-28 The Regents Of The University Of California 聚醣依赖性免疫治疗分子
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
RU2017142352A (ru) 2015-05-06 2019-06-06 Снипр Текнолоджиз Лимитед Изменение популяций микроорганизмов и модификация микробиоты
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
US11253616B2 (en) 2017-09-06 2022-02-22 The Trustees Of The University Of Pennsylvania Small molecules for dual function positron emission tomography (PET) and cell suicide switches
US20200316231A1 (en) * 2015-05-10 2020-10-08 The Trustees Of The University Of Pennsylvania Compositions And Methods For Imaging Immune Cells
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
WO2016187068A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3466967A1 (en) * 2015-05-18 2019-04-10 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US20180147271A1 (en) * 2015-05-18 2018-05-31 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
US10434153B1 (en) 2015-05-20 2019-10-08 Kim Leslie O'Neill Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
EP3297629A1 (en) 2015-05-20 2018-03-28 Novartis AG Pharmaceutical combination of everolimus with dactolisib
US10752670B2 (en) 2015-05-20 2020-08-25 Cellectis Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
WO2016187508A2 (en) 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens
SG10201913620QA (en) 2015-05-28 2020-03-30 Kite Pharma Inc Diagnostic methods for t cell therapy
JP7121496B2 (ja) * 2015-05-28 2022-08-18 アルモ・バイオサイエンシーズ・インコーポレイテッド 癌治療で使用するためのペグ化インターロイキン－１０
HK1246151A1 (zh) 2015-05-28 2018-09-07 凯德药业股份有限公司 为t细胞疗法而调理患者的方法
US20180161369A1 (en) 2015-05-29 2018-06-14 Fred Hutchinson Cancer Research Center Compositions for cellular immunotherapy
AU2016271147B2 (en) 2015-05-29 2022-09-08 Juno Therapeutics, Inc. Composition and methods for regulating inhibitory interactions in genetically engineered cells
MX2017015493A (es) 2015-05-30 2018-02-09 Molecular Templates Inc Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
AU2016270474A1 (en) 2015-06-04 2018-01-04 University Of Southern California Lym-1 and Lym-2 targeted CAR cell immunotherapy
SG10202003075UA (en) 2015-06-05 2020-05-28 Novartis Ag Flow-through paramagnetic particle-based cell separation and paramagnetic particle removal
EP3307319A4 (en) 2015-06-09 2019-05-22 Memorial Sloan Kettering Cancer Center T CELL RECEPTOR-SIMILAR ANTIBODIES SPECIFIC TO PEPTID OF THE LATENT EBV MEMBRANE PROTEIN 2A PRESENTED BY HUMAN HLA
EP4424326A3 (en) 2015-06-10 2024-11-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
EP3307738B1 (en) 2015-06-11 2022-04-20 The Regents of the University of Michigan Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
CN108603170A (zh) 2015-06-12 2018-09-28 莱蒂恩技术公司 用工程改造的t细胞治疗癌症的方法
CN107708741A (zh) * 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
CN105177031B (zh) * 2015-06-12 2018-04-24 北京艺妙神州医疗科技有限公司 嵌合抗原受体修饰的t细胞及其用途
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
CN115925971A (zh) 2015-06-19 2023-04-07 塞巴斯蒂安·科博尔德 Pd-1-cd28融合蛋白及其在医学中的用途
US11655452B2 (en) 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
US11059880B2 (en) 2015-06-30 2021-07-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
MA42902A (fr) * 2015-07-08 2018-05-16 Univ Johns Hopkins Lymphocytes infiltrant la moelle (mil) en tant que source de lymphocytes t pour une thérapie par des récepteurs chimériques d'un antigène (car)
WO2017011316A1 (en) 2015-07-10 2017-01-19 The Trustees Of The University Of Pennsylvania Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
IL315940A (en) 2015-07-28 2024-11-01 Univ Pennsylvania Altered monocytes/macrophages expressing chimeric antigen receptors and their uses
WO2017023803A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy
SG10201912734PA (en) 2015-08-05 2020-02-27 Yoo Young Pharm Co Ltd Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
WO2017027653A1 (en) 2015-08-11 2017-02-16 The Johns Hopkins University Assaying ovarian cyst fluid
US11352439B2 (en) 2015-08-13 2022-06-07 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) in immunotherapy
CN106467906B (zh) * 2015-08-20 2019-09-27 北京马力喏生物科技有限公司 构建体、转基因淋巴细胞及其制备方法和用途
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
CN108135932A (zh) * 2015-08-28 2018-06-08 宾夕法尼亚大学董事会 表达嵌合细胞内信号传导分子的细胞的方法和组合物
US10526408B2 (en) 2015-08-28 2020-01-07 Research Development Foundation Engineered antibody FC variants
EP3340998B1 (en) * 2015-08-28 2023-01-11 The Trustees of the University of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN108136014A (zh) * 2015-08-31 2018-06-08 蓝鸟生物公司 抗唾液酸tn嵌合抗原受体
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
ES2848478T3 (es) 2015-09-11 2021-08-09 Biosceptre Uk Ltd Receptores quiméricos para antígenos y usos de estos
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
CN108348606A (zh) 2015-09-18 2018-07-31 综合医院公司以麻省总医院名义经营 用于治疗癌症的抗趋除剂的局部递送
HK1259027A1 (zh) * 2015-09-18 2019-11-22 综合医院公司以麻省总医院名义经营 具有抗趋除特性的修饰的t细胞及其用途
KR20180050413A (ko) * 2015-09-22 2018-05-14 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Hiv 감염을 치료하기 위해 t 세포를 리디렉션시키는 방법
CA2999917A1 (en) 2015-09-24 2017-03-30 Abvitro Llc Hiv antibody compositions and methods of use
CN108369230B (zh) 2015-09-25 2021-09-17 阿布维特罗有限责任公司 用于对天然配对t细胞受体序列进行t细胞受体靶向鉴别的高通量方法
US11365391B2 (en) 2015-09-28 2022-06-21 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
EP3355937A4 (en) 2015-09-28 2019-04-17 Regents of the University of Minnesota CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY
ES2809550T3 (es) * 2015-10-06 2021-03-04 Hope City Receptores de antígenos quiméricos dirigidos contra PSCA
US10392441B2 (en) 2015-10-07 2019-08-27 United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
WO2017059796A1 (en) 2015-10-08 2017-04-13 Shanghai Sidansai Biotechnology Co., Ltd Activation and expansion of t cells
CN108138171B (zh) * 2015-10-08 2022-05-13 国立大学法人名古屋大学 表达嵌合抗原受体的基因修饰t细胞的制备方法
EP3359694A4 (en) * 2015-10-09 2019-07-17 Guardant Health, Inc. POPULATION-BASED TREATMENT TREATMENT USING CELL-FREE DNA
EP3660044A1 (en) 2015-10-09 2020-06-03 Miltenyi Biotec Technology, Inc. Chimeric antigen receptors and methods of use
CN105153315B (zh) * 2015-10-09 2019-04-02 重庆精准生物技术有限公司 免疫抑制受体联合肿瘤抗原嵌合受体及其应用
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CN105924530B (zh) * 2015-10-13 2019-08-06 中国人民解放军总医院 嵌合抗原受体及其基因和重组表达载体、car20-nkt细胞及其制备方法和应用
CN106755023A (zh) * 2015-10-15 2017-05-31 中国人民解放军军事医学科学院附属医院 带安全开关的嵌合抗原受体免疫细胞及其制备方法与应用
IL300420B2 (en) 2015-10-16 2024-09-01 Univ Columbia Compositions and methods for inhibition of lineage specific antigens
WO2017064222A1 (en) 2015-10-16 2017-04-20 Ludwig-Maximilians-Universität München Cxcr6-transduced t cells for targeted tumor therapy
AU2016341131A1 (en) 2015-10-19 2018-05-10 University Of Massachusetts Anti-cancer and anti-inflammatory therapeutics and methods thereof
KR20250089563A (ko) 2015-10-20 2025-06-18 카이트 파마 인코포레이티드 T 세포 요법을 위한 t 세포를 제조하는 방법
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
CN108474002B (zh) 2015-10-22 2023-05-23 朱诺治疗学有限公司 用于转导的方法、反应剂盒、反应剂和设备
AU2016341321A1 (en) * 2015-10-23 2018-06-07 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same
CN105132445B (zh) * 2015-10-23 2018-10-02 马健颖 一种特异识别肿瘤细胞的受体蛋白、t淋巴细胞及nk细胞
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
EP3368689B1 (en) 2015-10-28 2020-06-17 The Broad Institute, Inc. Composition for modulating immune responses by use of immune cell gene signature
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017079703A1 (en) 2015-11-05 2017-05-11 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
CN105384826A (zh) * 2015-11-19 2016-03-09 广州熙帝生物科技有限公司 表达嵌合抗原受体的脐血有核细胞及其应用
US11001622B2 (en) 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
CN116121281A (zh) * 2015-11-27 2023-05-16 卡瑟里克斯私人有限公司 经遗传修饰的细胞及其用途
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
EP3383419B1 (en) 2015-12-03 2022-08-03 Juno Therapeutics, Inc. Compositions and methods for reducing immune responses against chimeric antigen receptors
EP3384294B1 (en) 2015-12-04 2021-10-13 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
AU2016362129A1 (en) 2015-12-04 2018-06-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
WO2017095525A1 (en) * 2015-12-04 2017-06-08 David Scott Antigen-specific t cells for inducing immune tolerance
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
CA3008272A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3393468B1 (en) 2015-12-22 2022-09-14 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
CN117025539A (zh) 2015-12-28 2023-11-10 诺华股份有限公司 制备嵌合抗原受体表达细胞的方法
SG11201805451TA (en) 2015-12-30 2018-07-30 Novartis Ag Immune effector cell therapies with enhanced efficacy
EA201891589A1 (ru) 2016-01-08 2019-01-31 Те Риджентс Оф Те Юниверсити Оф Калифорния Условно активные гетеродимерные полипептиды и способы их применения
GB201600328D0 (en) 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
CN105950645A (zh) * 2016-01-11 2016-09-21 灏灵赛奥（天津）生物科技有限公司 Car-cd19抗原受体的人源化融合基因片段、其构建方法及应用
US10919950B2 (en) * 2016-01-14 2021-02-16 Seattle Children's Hospital Tumor-specific IFNA secretion by car T-cells to reprogram the solid tumor microenvironment
WO2017124001A2 (en) * 2016-01-14 2017-07-20 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for foxp3-derived peptides
US11382886B2 (en) 2016-01-15 2022-07-12 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
ES2942362T3 (es) 2016-01-21 2023-05-31 Pfizer Receptores quiméricos para el antígeno que se dirigen a la variante III del receptor del factor de crecimiento epidérmico
US10221242B2 (en) 2016-01-21 2019-03-05 Pfizer Inc. Antibodies specific for epidermal growth factor receptor variant III and their uses
CN105567640A (zh) * 2016-01-27 2016-05-11 苏州佰通生物科技有限公司 一种嵌合抗原受体脂肪干细胞及其制备方法
AU2017223460A1 (en) 2016-02-23 2018-09-13 Immune Design Corp. Multigenome retroviral vector preparations and methods and systems for producing and using same
US11542486B2 (en) 2016-03-02 2023-01-03 Board Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
WO2017160806A1 (en) * 2016-03-14 2017-09-21 Wisconsin Alumni Research Foundation Methods of t cell expansion and activation
EP3430549A1 (en) 2016-03-16 2019-01-23 Juno Therapeutics, Inc. Methods for adaptive design of a treatment regimen and related treatments
WO2017161208A1 (en) 2016-03-16 2017-09-21 Juno Therapeutics, Inc. Methods for determining dosing of a therapeutic agent and related treatments
NZ746168A (en) * 2016-03-17 2022-04-29 Univ Yamaguchi Immunocompetent cell and expression vector expressing regulatory factors of immune function
MX2018010415A (es) 2016-03-18 2018-11-29 Hutchinson Fred Cancer Res Composiciones y metodos para inmunoterapia de grupo de diferenciacion 20 (cd20).
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
RU2018136877A (ru) 2016-03-22 2020-04-22 СИЭТЛ ЧИЛДРЕН'С ХОСПИТАЛ (ДиБиЭй СИЭТЛ ЧИЛДРЕН'С РИСЕРЧ ИНСТИТЬЮТ) Способы раннего вмешательства для профилактики или улучшения состояния токсичности
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
CN109219445B (zh) * 2016-04-01 2022-08-26 上海煦顼技术有限公司 嵌合抗原受体修饰细胞治疗癌症的应用
DK3436030T3 (da) 2016-04-01 2022-11-21 Kite Pharma Inc Kimæriske receptorer og fremgangsmåder til anvendelse deraf
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
TWI761831B (zh) 2016-04-01 2022-04-21 美商凱特製藥公司 嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途
AU2017240801A1 (en) 2016-04-01 2018-10-25 Amgen Inc. Chimeric receptors to FLT3 and methods of use thereof
US10603380B2 (en) 2016-04-01 2020-03-31 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
JP2019510785A (ja) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法
CN108778312B (zh) 2016-04-08 2022-07-15 爱默蕾大学 使用基于细胞的疗法治疗癌症和传染病的方法
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN106399255B (zh) * 2016-04-13 2019-10-18 阿思科力(苏州)生物科技有限公司 Pd-1 car-t细胞及其制备方法和应用
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
IL310729A (en) 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
IL262321B2 (en) 2016-04-15 2024-09-01 Novartis Ag Preparations and methods for selective protein expression
WO2017181148A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
CN105907719B (zh) * 2016-04-18 2019-10-18 阿思科力(苏州)生物科技有限公司 Anti ROBO1 CAR-T细胞及其制备和应用
CN121102467A (zh) * 2016-04-22 2025-12-12 克莱格医学有限公司 用于细胞免疫疗法的组合物和方法
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
IL302641A (en) 2016-05-06 2023-07-01 Juno Therapeutics Inc Genetically Engineered Cells and Methods of Making the Same
US11261223B2 (en) * 2016-05-11 2022-03-01 The University Of Chicago Methods of treating cancers with CT45 targeted therapies
CA3025516A1 (en) * 2016-05-27 2017-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
WO2017205846A1 (en) 2016-05-27 2017-11-30 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of genome-editing molecules
CN105837693A (zh) * 2016-05-30 2016-08-10 李斯文 一种基于bcma的抗原嵌合受体及其制备方法和应用
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
AU2017274733A1 (en) 2016-06-03 2018-12-20 Memorial Sloan-Kettering Cancer Center Adoptive cell therapies as early treatment options
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
US11390658B2 (en) 2016-06-06 2022-07-19 St. Jude Children's Research Hospital Anti-CD7 chimeric antigen receptor and method of use thereof
MA45341A (fr) 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
JP2019522643A (ja) 2016-06-08 2019-08-15 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
IL300274A (en) 2016-06-08 2023-04-01 Abbvie Inc Antibodies against B7–H3 and conjugates of drug and antibody
EP3468598A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
WO2017214462A2 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
EP3468993A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
JP7591342B2 (ja) 2016-06-08 2024-11-28 プレシゲン，インコーポレイテッド Ｃｄ３３特異的キメラ抗原受容体
BR112018075649A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
CN107523545A (zh) * 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的杀伤性细胞及其用途
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN106117367B (zh) * 2016-06-24 2020-02-11 安徽未名细胞治疗有限公司 一种her-3特异性嵌合抗原受体及其应用
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
EP3475446A1 (en) 2016-06-27 2019-05-01 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
CA3026858A1 (en) 2016-06-30 2018-01-04 F. Hoffmann-La Roche Ag Improved adoptive t-cell therapy
US10501775B2 (en) 2016-07-12 2019-12-10 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CN109715173A (zh) 2016-07-15 2019-05-03 维拉克塔治疗公司 供基于nk细胞的疗法使用的hdac抑制剂
US20190336504A1 (en) 2016-07-15 2019-11-07 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
PL240585B1 (pl) * 2016-07-18 2022-05-02 Helix Biopharma Corp Chimeryczny receptor antygenowy (CAR), komórki immunologiczne zawierające CAR oraz kompozycja farmaceutyczna je zawierająca do leczenia nowotworów
EP3487878A4 (en) 2016-07-20 2020-03-25 University of Utah Research Foundation CAR-T CD229 LYMPHOCYTES AND METHODS OF USE
US11384156B2 (en) 2016-07-25 2022-07-12 The Nemours Foundation Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
SG11201900677SA (en) 2016-07-28 2019-02-27 Novartis Ag Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
MX2019001186A (es) 2016-07-29 2019-08-29 Juno Therapeutics Inc Metodos para evaluar la presencia o la ausencia de un virus capaz de replicacion.
US12304935B2 (en) 2016-07-29 2025-05-20 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
US20240018268A1 (en) * 2016-07-29 2024-01-18 Juno Therapeutics, Inc. Anti-idiotypic antibodies against anti-cd19 antibodies
MX2019001469A (es) 2016-08-01 2019-10-02 Novartis Ag Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US11078481B1 (en) 2016-08-03 2021-08-03 KSQ Therapeutics, Inc. Methods for screening for cancer targets
US11630103B2 (en) 2016-08-17 2023-04-18 The Broad Institute, Inc. Product and methods useful for modulating and evaluating immune responses
EP4342978A3 (en) 2016-09-01 2024-07-03 Chimera Bioengineering Inc. Gold optimized car t-cells
US11701384B2 (en) 2016-09-02 2023-07-18 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
US11453712B2 (en) 2016-09-02 2022-09-27 Lentigen Technology Inc. Compositions and methods for treating cancer with DuoCARs
US11078483B1 (en) 2016-09-02 2021-08-03 KSQ Therapeutics, Inc. Methods for measuring and improving CRISPR reagent function
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
RU2755725C2 (ru) 2016-09-12 2021-09-20 Джуно Терапьютикс, Инк. Сборочные узлы перфузионных биореакторных мешков
US11077178B2 (en) * 2016-09-21 2021-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use
JP2020501512A (ja) * 2016-09-23 2020-01-23 ユニバーシティ オブ サザン カリフォルニア キメラ抗原受容体およびその組成物ならびにそれらの使用の方法
EP4538295A3 (en) 2016-09-28 2025-06-18 Kite Pharma, Inc. Antigen binding molecules and methods of use thereof
EP4353319A3 (en) 2016-09-28 2024-06-05 Atossa Therapeutics, Inc. Methods of adoptive cell therapy
US12499971B2 (en) 2016-09-28 2025-12-16 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
AU2017338827B2 (en) 2016-10-03 2023-08-31 Juno Therapeutics, Inc. HPV-specific binding molecules
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
AU2017341047B2 (en) 2016-10-07 2024-10-10 Novartis Ag Chimeric antigen receptors for the treatment of cancer
BR112019007100A2 (pt) 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CN107151654B (zh) * 2016-10-11 2020-05-05 深圳宾德生物技术有限公司 一种人源t淋巴细胞的培养基及其制备方法和应用
ES2939646T3 (es) 2016-10-13 2023-04-25 Juno Therapeutics Inc Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano
CN107936120B (zh) * 2016-10-13 2021-03-09 上海赛比曼生物科技有限公司 Cd19靶向性的嵌合抗原受体及其制法和应用
CA3041068A1 (en) 2016-10-18 2018-04-26 Regents Of The University Of Minnesota Tumor infiltrating lymphocytes and methods of therapy
KR102613430B1 (ko) 2016-10-19 2023-12-18 더 스크립스 리서치 인스티튜트 인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
EP3872180A1 (en) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
EP4092049A1 (en) 2016-10-20 2022-11-23 Celgene Corporation Cereblon-based heterodimerizable chimeric antigen receptors
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CA3040914A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
WO2018085731A2 (en) 2016-11-03 2018-05-11 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and a btk inhibitor
EP3534968A4 (en) 2016-11-04 2020-07-01 Bluebird Bio, Inc. ANTI-BCMA T CAR LYMPHOCYTE COMPOSITIONS
US12227578B2 (en) 2016-11-11 2025-02-18 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US11440958B2 (en) * 2016-11-22 2022-09-13 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
BR112019010470A2 (pt) 2016-11-23 2019-09-10 Novartis Ag métodos de realce de resposta imune com everolimo, dactolisib ou ambos
US20190030073A1 (en) * 2016-12-02 2019-01-31 Cartesian Therapeutics, Inc. Cancer immunotherapy with highly enriched cd8+ chimeric antigen receptor t cells
ES2961666T3 (es) 2016-12-03 2024-03-13 Juno Therapeutics Inc Métodos para determinar la dosificación de células CAR-T
JP2019536460A (ja) 2016-12-03 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Ｃａｒ−ｔ細胞の調節方法
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
WO2018106732A1 (en) 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
CN108165568B (zh) * 2016-12-07 2020-12-08 上海恒润达生生物科技有限公司 一种培养CD19CAR-iNKT细胞方法及用途
CN107058315B (zh) * 2016-12-08 2019-11-08 上海优卡迪生物医药科技有限公司 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
CA3045665A1 (en) 2016-12-12 2018-06-21 Seattle Children's Hospital (dba Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
CN108218994A (zh) * 2016-12-14 2018-06-29 上海恒润达生生物科技有限公司 一种方法培养t记忆干细胞
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CA3047313A1 (en) 2016-12-16 2018-06-21 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
US11447562B2 (en) 2017-01-01 2022-09-20 Chi-Yu Gregory Lee RP215 chimeric antigen receptor construct and methods of making and using same
EP3609536B1 (en) 2017-01-05 2022-03-09 Innovative Cellular Therapeutics Holdings, Ltd. Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
CN110121336A (zh) 2017-01-05 2019-08-13 弗莱德哈钦森癌症研究中心 改善疫苗功效的系统和方法
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
US20200121719A1 (en) 2017-01-06 2020-04-23 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
WO2018129336A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
EP3346001A1 (en) * 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
CN108285920A (zh) * 2017-01-09 2018-07-17 上海恒润达生生物科技有限公司 一种体内检测cart细胞表达的技术及其用途
JP7429338B2 (ja) 2017-01-10 2024-02-08 ジュノー セラピューティクス インコーポレイテッド 細胞療法および関連方法のエピジェネティック解析
GB201700553D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
WO2018132695A1 (en) * 2017-01-13 2018-07-19 Celdara Medical, Llc Chimeric antigen receptors targeting tim-1
MX2019008538A (es) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN108342363B (zh) * 2017-01-25 2021-02-12 北京马力喏生物科技有限公司 共表达抗msln嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
RU2674894C2 (ru) * 2017-01-30 2018-12-13 Общество с ограниченной ответственностью "ПЛАНТА" Новые люциферазы и способы их использования
WO2018144597A1 (en) * 2017-01-31 2018-08-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of sensitizing cancer cells to immune cell killing
JP2020506700A (ja) 2017-01-31 2020-03-05 ノバルティス アーゲー 多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
BR112019016657A2 (pt) 2017-02-12 2020-04-07 Neon Therapeutics, Inc. métodos baseados em hla e composições e usos destes
ES2900233T3 (es) * 2017-02-14 2022-03-16 Kite Pharma Inc Moléculas que se unen a CD70 y métodos de uso de las mismas
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
AU2018224856B2 (en) 2017-02-27 2025-04-03 Juno Therapeutics, Inc. Compositions, articles of manufacture and methods related to dosing in cell therapy
EP3585880A1 (en) 2017-02-27 2020-01-01 Life Technologies Corporation Expansion of populations of t cells by the use of modified serum free media
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
JP7341900B2 (ja) * 2017-03-03 2023-09-11 オブシディアン セラピューティクス， インコーポレイテッド 免疫療法のためのｃｄ１９組成物及び方法
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
WO2018169922A2 (en) 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
KR102771581B1 (ko) 2017-03-14 2025-02-25 주노 쎄러퓨티크스 인코퍼레이티드 극저온 보관 방법
IL268781B2 (en) 2017-03-16 2025-09-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
WO2018170021A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
AU2018236461B2 (en) 2017-03-17 2025-03-27 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
SG11201907434RA (en) 2017-03-22 2019-10-30 Novartis Ag Compositions and methods for immunooncology
EP3600395A4 (en) 2017-03-23 2021-05-05 The General Hospital Corporation BLOCKING OF CXCR4 / CXCR7 AND TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASE
CN110997719B (zh) * 2017-03-24 2020-12-11 莱蒂恩技术公司 用于用抗cd33免疫疗法治疗癌症的组合物和方法
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
WO2018183842A1 (en) 2017-03-31 2018-10-04 The Board Of Trustees Of The Leland Standford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
SG11201907744QA (en) 2017-04-01 2019-09-27 Avm Biotechnology Llc Replacement of cytotoxic preconditioning before cellular immunotherapy
WO2018183921A1 (en) 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2018187356A2 (en) 2017-04-03 2018-10-11 Neon Therapeutics, Inc. Protein antigens and uses thereof
CN110494158A (zh) 2017-04-03 2019-11-22 凯德药业股份有限公司 使用包含优化的多功能t细胞的嵌合受体t细胞进行治疗
JP7284707B2 (ja) 2017-04-07 2023-05-31 ジュノー セラピューティクス インコーポレイテッド 前立腺特異的膜抗原（ｐｓｍａ）またはその改変型を発現する操作された細胞および関連方法
US20200071773A1 (en) 2017-04-12 2020-03-05 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
MA54103A (fr) 2017-04-14 2021-09-15 Juno Therapeutics Inc Procédés d'évaluation de la glycosylation de surface cellulaire
CA3057394A1 (en) 2017-04-14 2018-10-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
CN108727497A (zh) * 2017-04-17 2018-11-02 沈阳美达博生物科技有限公司 一种cd19抗体及其应用
EP3612629A1 (en) 2017-04-18 2020-02-26 The Broad Institute, Inc. Compositions for detecting secretion and methods of use
IL269716B2 (en) 2017-04-18 2025-07-01 Fujifilm Cellular Dynamics Inc Antigen-specific immune effector cells
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
CA3059939A1 (en) 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
SG11201909931PA (en) 2017-04-27 2019-11-28 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US20200078404A1 (en) 2017-05-01 2020-03-12 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
CN107226867B (zh) * 2017-07-25 2018-02-06 重庆精准生物技术有限公司 抗人cd19抗原的嵌合抗原受体及其应用
WO2018201794A1 (zh) * 2017-05-02 2018-11-08 重庆精准生物技术有限公司 抗人cd19抗原的嵌合抗原受体及其应用
CA3062874A1 (en) * 2017-05-10 2018-11-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2018209324A2 (en) 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
JP7356354B2 (ja) 2017-05-12 2023-10-04 クリスパー セラピューティクス アクチェンゲゼルシャフト 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CN110650975B (zh) 2017-05-15 2024-04-05 美国卫生和人力服务部 双顺反子嵌合抗原受体及其用途
US10415017B2 (en) 2017-05-17 2019-09-17 Thunder Biotech, Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
EP3625342B1 (en) 2017-05-18 2022-08-24 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
EP3406733A1 (en) 2017-05-24 2018-11-28 SIB Swiss Institute of Bioinformatics Kinase mutants and uses thereof
WO2018218072A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Compositions and methods for an improved antitumor immune response
ES3041991T3 (en) 2017-05-25 2025-11-17 Leidos Inc Pd-1 and ctla-4 dual inhibitor peptides
KR20210118479A (ko) 2017-05-26 2021-09-30 카이트 파마 인코포레이티드 배아 중간엽 전구 세포를 제조하고 사용하는 방법
US11566223B2 (en) 2017-06-01 2023-01-31 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cell preparation and uses thereof
US12384830B2 (en) 2017-06-02 2025-08-12 Regents Of The University Of Minnesota Compositions and methods for improving immunotherapy
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
US20200098480A1 (en) * 2017-06-02 2020-03-26 Mayo Foundation For Medical Education And Research System and method for providing clinical outcomes driven expertise for disease treatment
US11740231B2 (en) 2017-06-02 2023-08-29 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
CA3061959A1 (en) 2017-06-09 2018-12-13 Providence Health & Services - Oregon Utilization of cd39 and cd103 for identification of human tumor reactive t cells for treatment of cancer
US11897953B2 (en) 2017-06-14 2024-02-13 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
PL3538645T3 (pl) 2017-06-20 2021-11-08 Institut Curie Komórki odpornościowe z defektem suv39h1
JP2020524512A (ja) 2017-06-21 2020-08-20 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
ES3014942T3 (en) 2017-06-21 2025-04-28 Univ North Carolina Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
AU2018288863A1 (en) 2017-06-22 2020-01-30 Board Of Regents, The University Of Texas System Methods for producing regulatory immune cells and uses thereof
KR20200021087A (ko) 2017-06-22 2020-02-27 노파르티스 아게 Cd73에 대한 항체 분자 및 이의 용도
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
US10806780B2 (en) 2017-06-28 2020-10-20 Regeneron Pharmaceuticals, Inc. Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
EP3644721A1 (en) 2017-06-29 2020-05-06 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
JP2020530307A (ja) 2017-06-30 2020-10-22 インティマ・バイオサイエンス，インコーポレーテッド 遺伝子治療のためのアデノ随伴ウイルスベクター
AU2018292181B2 (en) 2017-06-30 2025-04-10 Cellectis Cellular immunotherapy for repetitive administration
US11235004B2 (en) 2017-06-30 2022-02-01 Innovative Cellular Therapeutics Holdings, Ltd. Lymphocyte cell lines and uses thereof
CN107287164A (zh) * 2017-07-07 2017-10-24 青岛协和华美医学诊断技术有限公司 靶向cd19的嵌合抗原受体t细胞、制备方法及应用
EP3648799A4 (en) 2017-07-07 2021-06-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with mutated cd28 costimulatory domains
CN107365798B (zh) * 2017-07-13 2020-07-14 山东省齐鲁细胞治疗工程技术有限公司 一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
KR102869563B1 (ko) 2017-07-17 2025-10-10 얀센 바이오테크 인코포레이티드 피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법
BR112020001719A2 (pt) 2017-07-29 2020-07-21 Juno Therapeutics Inc reagentes para expansão de células que expressam receptores recombinantes
WO2019028051A1 (en) 2017-07-31 2019-02-07 Lentigen Technology, Inc. COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY
WO2019028096A1 (en) 2017-08-02 2019-02-07 The Wistar Institute Of Anatomy And Biology METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
WO2019028417A1 (en) 2017-08-03 2019-02-07 The Scripps Research Institute MODIFICATION OF B-LYMPHOCYTE RECEPTORS IN B-LYMPHOCYTES
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
IL319255A (en) 2017-08-07 2025-04-01 Univ Johns Hopkins Methods and materials for cancer assessment and treatment
MX2020001490A (es) 2017-08-09 2020-08-06 Juno Therapeutics Inc Metodos para producir composiciones de celulas geneticamente modificadas y composiciones relacionadas.
BR112020001601A2 (pt) 2017-08-09 2020-08-11 Juno Therapeutics Inc métodos e composições para preparar células geneticamente manipuladas
JP2020530291A (ja) 2017-08-10 2020-10-22 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞受容体欠損キメラ抗原受容体ｔ細胞およびその使用方法
KR20200051646A (ko) 2017-08-17 2020-05-13 이케나 온콜로지, 인코포레이티드 Ahr 억제제 및 이의 용도
WO2019046832A1 (en) 2017-09-01 2019-03-07 Juno Therapeutics, Inc. GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
WO2019046052A1 (en) 2017-09-01 2019-03-07 Gpb Scientific, Llc METHODS FOR PREPARING THERAPEUTICALLY ACTIVE CELLS USING MICROFLUIDIC
EP3679370A1 (en) 2017-09-07 2020-07-15 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
KR20230052312A (ko) 2017-09-15 2023-04-19 카이트 파마 인코포레이티드 관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템
EP3681991A1 (en) 2017-09-15 2020-07-22 Life Technologies Corporation Compositions and methods for culturing and expanding cells
CN107557337B (zh) * 2017-09-15 2020-06-26 山东兴瑞生物科技有限公司 一种抗ror1安全型嵌合抗原受体修饰的免疫细胞及其应用
EP3684821A4 (en) * 2017-09-19 2021-06-16 The University Of British Columbia ANTI-HLA-A2 ANTIBODIES AND METHOD OF USING THEREOF
MX2020002901A (es) 2017-09-19 2020-07-22 Massachusetts Inst Technology Composiciones para la terapia con celulas t con receptores de antigeno quimerico y usos de las mismas.
CN109517820B (zh) 2017-09-20 2021-09-24 北京宇繁生物科技有限公司 一种靶向HPK1的gRNA以及HPK1基因编辑方法
KR102740924B1 (ko) 2017-09-20 2024-12-13 더 유니버시티 오브 브리티쉬 콜롬비아 신규한 항-ｈｌａ-ａ2 항체 및 이의 용도
KR102338449B1 (ko) 2017-09-21 2021-12-10 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물
WO2019060713A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. ANTIGEN-BINDING MOLECULES AND METHODS OF USE THEREOF
CA3076613A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CA3076099A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. Linkers for chimeric antigen receptors
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
MX2020007357A (es) * 2017-09-26 2021-08-11 Longwood Univ Reporte de antígeno quimérico específico de pd1 como una inmunoterapia.
CN109554349B (zh) * 2017-09-27 2022-06-24 亘喜生物科技（上海）有限公司 Pd-1基因表达沉默的工程化免疫细胞
EP3687575A4 (en) * 2017-09-29 2021-06-30 National Health Research Institutes METHODS AND COMPOSITIONS FOR INCREASING SURVIVAL AND FUNCTIONALITY OF ANTITUMOR AND ANTIVIRUS T CELLS
EP3695408A4 (en) 2017-10-02 2021-12-15 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
EP3694875A1 (en) 2017-10-09 2020-08-19 Wisconsin Alumni Research Foundation Antibodies targeting glioblastoma stem-like cells and methods of use thereof
CA3198255A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
WO2019075385A1 (en) 2017-10-12 2019-04-18 Board Of Regents, The University Of Texas System T-LYMPHOCYTE COMPOSITIONS FOR IMMUNOTHERAPY
CA3079407A1 (en) 2017-10-18 2019-04-25 Novartis Ag Compositions and methods for selective protein degradation
EA202090974A1 (ru) 2017-10-18 2020-08-05 Элпайн Иммьюн Сайенсиз, Инк. Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы
TWI866888B (zh) 2017-10-18 2024-12-21 美商凱特製藥公司 投與嵌合抗原受體免疫療法之方法
CN109694854B (zh) * 2017-10-20 2023-11-21 亘喜生物科技（上海）有限公司 通用型嵌合抗原受体t细胞制备技术
US11732257B2 (en) 2017-10-23 2023-08-22 Massachusetts Institute Of Technology Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
WO2019084234A1 (en) * 2017-10-26 2019-05-02 St. Jude Childen's Research Hospital, Inc. METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS
WO2019084427A1 (en) 2017-10-27 2019-05-02 Kite Pharma, Inc. T-LYMPHOCYTE RECEPTOR ANTIGEN BINDING MOLECULES AND METHODS OF USE THEREOF
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
KR20200075000A (ko) 2017-11-01 2020-06-25 에디타스 메디신, 인코포레이티드 면역요법을 위한 t 세포 내 tgfbr2의 crispr-cas9 편집 방법, 조성물 및 성분
CA3080509A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for producing a t cell composition
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
PL3704230T3 (pl) 2017-11-01 2025-02-24 Juno Therapeutics, Inc. Proces wytwarzania kompozycji terapeutycznych z komórek zmodyfikowanych genetycznie
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
WO2019090110A1 (en) 2017-11-03 2019-05-09 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-ror1 immunotherapy
EP3703731A4 (en) 2017-11-04 2021-07-21 Aravive Biologics, Inc. METHOD OF TREATMENT OF METASTATIC CANCER USING AXL DECOY RECEPTORS
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
WO2019090202A1 (en) 2017-11-06 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy
CA3079999A1 (en) * 2017-11-07 2019-05-16 The Board Of Regents Of The University Of Texas System Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
EP3706904A1 (en) 2017-11-10 2020-09-16 Juno Therapeutics, Inc. Closed-system cryogenic vessels
US11802163B2 (en) 2017-11-10 2023-10-31 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting glypican-3 or mesothelin
US12018080B2 (en) 2017-11-13 2024-06-25 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
IL314701A (en) 2017-11-14 2024-10-01 Arcellx Inc Multifunctional immune cell therapies
JP7285267B2 (ja) 2017-11-14 2023-06-01 アーセルクス インコーポレイテッド Ｄドメイン含有ポリペプチドおよびその使用
AU2018369883A1 (en) 2017-11-15 2020-05-28 Novartis Ag BCMA-targeting chimeric antigen receptor, CD19-targeting chimeric antigen receptor, and combination therapies
EP3710471A1 (en) 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
CA3083118A1 (en) * 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
CN109837244A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种敲除pd1的靶向cd19的嵌合抗原受体t细胞及其制备方法和应用
SG11202005005YA (en) 2017-11-30 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
KR20200116081A (ko) 2017-12-01 2020-10-08 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포의 투약 및 조절 방법
US12084514B2 (en) 2017-12-04 2024-09-10 The Board Of Regents Of The University Of Oklahoma Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
WO2019113557A1 (en) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Process for producing a composition of engineered t cells
EP3720949A1 (en) 2017-12-08 2020-10-14 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
JP2021505615A (ja) 2017-12-08 2021-02-18 ジュノー セラピューティクス インコーポレイテッド 細胞療法および関連方法のための表現型マーカー
US11766455B2 (en) 2017-12-14 2023-09-26 Ezy Biotech Llc Subject-specific tumor inhibiting cells and the use thereof
JP7565795B2 (ja) 2017-12-15 2024-10-11 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
JP2021506260A (ja) 2017-12-15 2021-02-22 ジュノー セラピューティクス インコーポレイテッド 抗ｃｃｔ５結合分子およびその使用方法
WO2019117976A1 (en) 2017-12-17 2019-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide hydrogels and use thereof
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
CN108018312B (zh) * 2017-12-20 2019-09-10 上海优卡迪生物医药科技有限公司 一种t淋巴细胞白血病的car-t治疗载体及其构建方法和应用
EP3728282B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
GB201721833D0 (en) * 2017-12-22 2018-02-07 Cancer Research Tech Ltd Fusion proteins
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN109970866B (zh) * 2017-12-28 2022-10-04 上海细胞治疗研究院 一种cd28双向激活共刺激分子受体及其用途
CN109971712B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
CN109970864A (zh) * 2017-12-28 2019-07-05 上海细胞治疗研究院 一种双向激活共刺激分子受体及其用途
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
US12491153B2 (en) 2018-01-03 2025-12-09 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
US20190211109A1 (en) * 2018-01-05 2019-07-11 Maxcyte, Inc. Chronic car treatment for cancer
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
WO2019139972A1 (en) 2018-01-09 2019-07-18 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
JP2021510540A (ja) * 2018-01-11 2021-04-30 イノベイティブ セルラー セラピューティクス インク．Ｉｎｎｏｖａｔｉｖｅ Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 修飾細胞の増幅およびその応用
US10561686B2 (en) 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
TW201932593A (zh) 2018-01-15 2019-08-16 美商輝瑞大藥廠 合併投與嵌合抗原受體之免疫療法與4-1bb促效劑的方法
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
IL312674A (en) 2018-01-29 2024-07-01 Merck Patent Gmbh GCN2 inhibitors and uses thereof
EP3746075B1 (en) 2018-01-29 2025-09-03 Merck Patent GmbH Gcn2 inhibitors and uses thereof
KR102115236B1 (ko) * 2018-01-29 2020-05-27 (주)에스엠티바이오 췌장 또는 담관계암 치료를 위한 키메라 항원 수용체
EP3746117A1 (en) 2018-01-31 2020-12-09 Celgene Corporation Combination therapy using adoptive cell therapy and checkpoint inhibitor
US11535903B2 (en) 2018-01-31 2022-12-27 Juno Therapeutics, Inc. Methods and reagents for assessing the presence or absence of replication competent virus
AU2019215031B2 (en) 2018-01-31 2025-10-09 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019152957A1 (en) 2018-02-02 2019-08-08 Arizona Board Of Regents On Behalf Of Arizona State University Dna-chimeric antigen receptor t cells for immunotherapy
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
US20210087511A1 (en) * 2018-02-09 2021-03-25 Global Life Sciences Solutions Usa Llc Bioprocessing methods for cell therapy
US20230183313A1 (en) * 2018-02-11 2023-06-15 Jiangsu Hengrui Medicine Co., Ltd. Isolated chimeric antigen receptor, modified t cell comprising same and use thereof
CN110157677A (zh) * 2018-02-12 2019-08-23 深圳宾德生物技术有限公司 一种靶向性t淋巴细胞及其制备方法和应用
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN111712494A (zh) 2018-02-13 2020-09-25 吉利德科学公司 Pd-1/pd-l1抑制剂
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US20200377609A1 (en) 2018-02-14 2020-12-03 Kite Pharma, Inc. Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
SG11202007513PA (en) 2018-02-16 2020-09-29 Kite Pharma Inc Modified pluripotent stem cells and methods of making and use
KR20200144093A (ko) 2018-02-17 2020-12-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 막 단백질 전달을 위한 조성물 및 방법
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
WO2019173324A1 (en) 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
WO2019170845A1 (en) 2018-03-09 2019-09-12 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
WO2019175328A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4pathwayactivationandusethereoffortreatingcancer
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2019178420A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
MX2020010460A (es) 2018-04-05 2021-01-29 Juno Therapeutics Inc Receptores de células t, y células diseñadas que expresan los mismos.
MA52656A (fr) 2018-04-05 2021-02-17 Editas Medicine Inc Procédés de production de cellules exprimant un récepteur recombinant et compositions associées
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
AU2019249221A1 (en) 2018-04-06 2020-10-22 The Regents Of The University Of California Methods of treating glioblastomas
EP3773632A4 (en) 2018-04-06 2022-05-18 The Regents of The University of California Methods of treating egfrviii expressing glioblastomas
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI842703B (zh) 2018-04-10 2024-05-21 美商安進公司 Dll3 的嵌合受體及其使用方法
SG11202009881WA (en) 2018-04-12 2020-11-27 Kite Pharma Inc Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
WO2019200252A1 (en) 2018-04-13 2019-10-17 The Johns Hopkins University Non-invasive detection of response to immunotherapy
JP7447014B2 (ja) 2018-04-13 2024-03-11 サンガモ セラピューティクス フランス インターロイキン２３受容体に特異的なキメラ抗原受容体
WO2019200250A1 (en) 2018-04-13 2019-10-17 Velculescu Victor E Non-invasive detection of response to a targeted therapy
WO2019204269A1 (en) 2018-04-16 2019-10-24 Board Of Regents, The University Of Texas System Human kynureninase enzymes and uses thereof
WO2019204257A1 (en) 2018-04-16 2019-10-24 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
US10869888B2 (en) * 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
JP7527641B2 (ja) 2018-04-18 2024-08-05 アブクロン・インコーポレイテッド スイッチ分子及びスイッチャブルキメラ抗原受容体
EP4600247A3 (en) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US20210161958A1 (en) * 2018-04-19 2021-06-03 The Trustees Of The University Of Pennsylvania Compositions and methods for treating melanoma with a chimeric antigen receptor
EP3784669B1 (en) 2018-04-24 2023-10-25 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof
PT3784666T (pt) 2018-04-24 2022-06-06 Merck Patent Gmbh Compostos antiproliferação e utilizações dos mesmos
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
CN112055695A (zh) * 2018-05-01 2020-12-08 弗莱德哈钦森癌症研究中心 用于基因表达的纳米粒子和其用途
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210095001A1 (en) * 2018-05-02 2021-04-01 The Trustees Of The University Of Pennsylvania Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells
CN108753774B (zh) * 2018-05-03 2021-03-30 山东省齐鲁细胞治疗工程技术有限公司 干扰il-6表达的cd19-car-t细胞及其应用
EP3787751A1 (en) 2018-05-03 2021-03-10 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
EP3790958A1 (en) 2018-05-08 2021-03-17 Life Technologies Corporation Compositions and methods for culturing and expanding cells
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
CN112118845B (zh) 2018-05-14 2023-06-13 吉利德科学公司 Mcl-1抑制剂
US20210198747A1 (en) 2018-05-18 2021-07-01 The Johns Hopkins University Cell-free dna for assessing and/or treating cancer
KR20210008408A (ko) 2018-05-23 2021-01-21 싱가포르국립대학교 T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
CN108715859B (zh) * 2018-05-31 2021-08-03 中国医学科学院血液病医院(中国医学科学院血液学研究所) 靶向cd22的嵌合抗原受体及其应用
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3101991A1 (en) * 2018-06-01 2019-12-05 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
CA3101856A1 (en) 2018-06-01 2019-12-05 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
US20210123075A1 (en) 2018-06-08 2021-04-29 Novartis Ag Compositions and methods for immunooncology
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
KR20190141511A (ko) * 2018-06-14 2019-12-24 주식회사 녹십자랩셀 신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
EP3810764A2 (en) 2018-06-21 2021-04-28 B-Mogen Biotechnologies, Inc. Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
WO2019243888A1 (en) 2018-06-22 2019-12-26 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN112638402A (zh) 2018-07-03 2021-04-09 Sotio有限责任公司 与增强葡萄糖输入的反式代谢分子组合的嵌合受体及其治疗用途
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR20230159715A (ko) 2018-07-13 2023-11-21 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2020017479A1 (ja) 2018-07-17 2020-01-23 ノイルイミューン・バイオテック株式会社 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
JP7459046B2 (ja) 2018-07-18 2024-04-01 アムジエン・インコーポレーテツド Ｓｔｅａｐ１に対するキメラ受容体及びその使用方法
WO2020018825A1 (en) 2018-07-19 2020-01-23 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with bcma specificity and uses thereof
AU2019311077B2 (en) 2018-07-23 2025-05-29 Heidelberg Pharma Research Gmbh Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
CN108949759B (zh) * 2018-07-23 2021-06-01 合肥一兮生物科技有限公司 敲减人IL-15的siRNA、CD19 CAR表达载体、CAR-T细胞及构建方法和应用
SG11202101014XA (en) 2018-08-02 2021-02-25 Kite Pharma Inc Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
JP7538109B2 (ja) 2018-08-09 2024-08-21 ジュノー セラピューティクス インコーポレイテッド 組み込まれた核酸を評価するための方法
CN113474450A (zh) 2018-08-09 2021-10-01 朱诺治疗学股份有限公司 产生工程化细胞的方法以及所述工程化细胞的组合物
WO2020032784A1 (ko) 2018-08-10 2020-02-13 주식회사 유틸렉스 Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포
IL280322B2 (en) 2018-08-14 2025-06-01 Sotio Llc Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof
WO2020041384A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. 3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
CN110856724B (zh) * 2018-08-24 2022-05-27 杭州康万达医药科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用
MX2021002415A (es) 2018-08-28 2021-09-21 Vor Biopharma Inc Celulas madre hematopoyeticas modificadas geneticamente y usos de las mismas.
BR112021003830A2 (pt) 2018-08-28 2021-07-20 Fred Hutchinson Cancer Research Center métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida
JP7560882B2 (ja) 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
CN112638947B (zh) 2018-08-30 2022-09-30 上海斯丹赛生物技术有限公司 用于治疗实体瘤的嵌合抗原受体细胞
WO2020047452A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
US11866494B2 (en) * 2018-08-31 2024-01-09 Innovative Cellular Therapeutics Holdings, Ltd. CAR T therapy through uses of co-stimulation
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
US12366580B2 (en) 2018-09-11 2025-07-22 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
WO2020061376A2 (en) 2018-09-19 2020-03-26 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
US11584799B2 (en) 2018-09-24 2023-02-21 Medical College Of Wisconsin, Inc. Anti-CD30 antibodies and methods for treating CD30+ cancer
EP3856763A1 (en) 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
WO2020069409A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
SG11202103235PA (en) 2018-10-01 2021-04-29 Adicet Bio Inc COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
JP7401538B2 (ja) 2018-10-22 2023-12-19 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド 抗ｃｌｄｎ１８．２抗体およびその使用
JP7569313B2 (ja) 2018-10-23 2024-10-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｎｙ－ｅｓｏ－１ ｔ細胞受容体およびそれらの使用の方法
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
EP3870146A4 (en) * 2018-10-25 2022-08-10 Innovative Cellular Therapeutics Holdings, Ltd. Increase or maintaining t-cell subpopulations in adoptive t-cell therapy
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
US20210388389A1 (en) 2018-10-30 2021-12-16 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
JP7582940B2 (ja) 2018-10-31 2024-11-13 ジュノ セラピューティクス ゲーエムベーハー 細胞の選択および刺激のための方法ならびにそのための装置
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
CN113227089B (zh) 2018-10-31 2024-07-05 吉利德科学公司 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
WO2020088631A1 (en) 2018-11-01 2020-05-07 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
KR20210113169A (ko) 2018-11-01 2021-09-15 주노 쎄러퓨티크스 인코퍼레이티드 Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
EP3877054B1 (en) 2018-11-06 2023-11-01 Juno Therapeutics, Inc. Process for producing genetically engineered t cells
CN109467604A (zh) * 2018-11-07 2019-03-15 南京卡提医学科技有限公司 嵌合抗原受体DAP12-T2A-CD8α-CD19scFv-TREM1及其用途
CN113260368B (zh) * 2018-11-07 2023-08-29 舒迪安生物技术公司 抗gpc3嵌合抗原受体(car)与反式共刺激分子的组合及其治疗用途
CN109503717A (zh) * 2018-11-07 2019-03-22 南京卡提医学科技有限公司 嵌合抗原受体DAP12-T2A-CD8α-CD19scfv-NKp44及其用途
US12263190B2 (en) 2018-11-08 2025-04-01 Juno Therapeutics, Inc. Methods and combinations for treatment and T cell modulation
JP2022513040A (ja) 2018-11-14 2022-02-07 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド コンパートメント特異的カーゴ送達のための組成物および方法
AU2019378883A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for T cell delivery
CN113271963A (zh) 2018-11-16 2021-08-17 朱诺治疗学股份有限公司 给予工程化t细胞以治疗b细胞恶性肿瘤的方法
EP3883955A1 (en) 2018-11-19 2021-09-29 Board of Regents, The University of Texas System A modular, polycistronic vector for car and tcr transduction
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
AU2019384145A1 (en) * 2018-11-20 2021-06-10 Innovative Cellular Therapeutics Holdings, Ltd. Modified cell expressing therapeutic agent and uses thereof
CA3121027A1 (en) 2018-11-28 2020-06-04 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
WO2020112493A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
AU2019387494A1 (en) 2018-11-30 2021-06-10 Juno Therapeutics, Inc. Methods for dosing and treatment of B cell malignancies in adoptive cell therapy
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
BR112021010354A2 (pt) 2018-11-30 2021-11-03 Juno Therapeutics Inc Métodos para o tratamento usando terapia celular adotiva
JP7671248B2 (ja) 2018-12-05 2025-05-01 ジェネンテック， インコーポレイテッド がんの免疫療法のための診断方法及び診断用組成物
JP2022519154A (ja) * 2018-12-07 2022-03-22 グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド 免疫療法のための組成物および方法
EP3894549B1 (en) 2018-12-10 2024-07-31 Amgen Inc. Mutated piggybac transposase
US12227551B2 (en) 2018-12-11 2025-02-18 Obsidian Therapeutics, Inc. Membrane bound IL12 compositions and methods for tunable regulation
CN113412117B (zh) 2018-12-12 2025-03-04 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
EP3670530A1 (en) 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
CN113271945A (zh) 2018-12-20 2021-08-17 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
SG11202106678PA (en) 2018-12-21 2021-07-29 Biontech Us Inc Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
SG11202107246TA (en) * 2019-01-06 2021-07-29 Abintus Bio Inc Car t cell methods and constructs
CA3123303A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
CA3128384A1 (en) 2019-02-04 2020-08-13 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2022520106A (ja) 2019-02-15 2022-03-28 ユニバーシティ オブ サザン カリフォルニア Ｌｙｍ－１およびｌｙｍ－２抗体組成物ならびに改善されたｃａｒ構築物
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
EP3930763A1 (en) 2019-02-25 2022-01-05 Novartis AG Mesoporous silica particles compositions for viral delivery
BR112021016984A2 (pt) 2019-03-01 2021-11-30 Allogene Therapeutics Inc Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
AU2020233284A1 (en) * 2019-03-01 2021-09-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
SG11202109172TA (en) 2019-03-08 2021-09-29 Obsidian Therapeutics Inc Human carbonic anhydrase 2 compositions and methods for tunable regulation
EP3935151A1 (en) 2019-03-08 2022-01-12 Klinikum der Universität München Ccr8 expressing lymphocytes for targeted tumor therapy
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020191079A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
WO2020187998A1 (en) 2019-03-19 2020-09-24 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
US20240317892A1 (en) * 2019-03-20 2024-09-26 Javelin Oncology, Inc Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
EP3946462A1 (en) 2019-04-02 2022-02-09 BicycleTX Limited Bicycle toxin conjugates and uses thereof
MX2021012216A (es) 2019-04-05 2022-01-24 Kymera Therapeutics Inc Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
BR112021019669A2 (pt) 2019-04-12 2021-12-07 C4 Therapeutics Inc Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3952885A4 (en) * 2019-04-12 2023-01-18 The Trustees of The University of Pennsylvania Compositions and methods comprising a high affinity chimeric antigen receptor (car) with cross-reactivity to clinically-relevant egfr mutated proteins
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020214957A1 (en) 2019-04-19 2020-10-22 Tcrcure Biopharma Corp. Anti-pd-1 antibodies and uses thereof
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
AU2020261411B2 (en) 2019-04-26 2025-10-02 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car T cells
BR112021021178A2 (pt) 2019-04-26 2022-03-15 Allogene Therapeutics Inc Receptores de antígeno quimérico resistentes ao rituximabe e usos destes
AU2020265679A1 (en) 2019-04-30 2021-12-23 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
CN113939319A (zh) 2019-04-30 2022-01-14 克里斯珀医疗股份公司 靶向cd19的基因工程化t细胞针对b细胞恶性肿瘤的同种异体细胞疗法
CN114007640A (zh) 2019-05-01 2022-02-01 朱诺治疗学股份有限公司 从修饰的cd247基因座表达嵌合受体的细胞、相关多核苷酸和方法
US20220184131A1 (en) 2019-05-01 2022-06-16 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
WO2020227177A1 (en) 2019-05-03 2020-11-12 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
CN113784732B (zh) 2019-05-07 2024-03-22 亘喜生物科技（上海）有限公司 靶向bcma的工程化免疫细胞及其用途
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
EP3972998A1 (en) 2019-05-21 2022-03-30 Novartis AG Cd19 binding molecules and uses thereof
CA3141162A1 (en) 2019-05-22 2020-11-26 Leidos, Inc. Lag3 binding peptides
US20220251538A1 (en) 2019-05-23 2022-08-11 Matjaz Vogelsang Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
EP4549555A3 (en) * 2019-05-24 2025-07-30 City of Hope Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN113905757A (zh) * 2019-06-05 2022-01-07 中外制药株式会社 抗体切割位点结合分子
EP3980453A4 (en) * 2019-06-07 2023-07-05 The Trustees of the University of Pennsylvania Dual car expressing t cells individually linked to cd28 and 4-1bb
AU2020287882A1 (en) 2019-06-07 2022-01-20 Juno Therapeutics, Inc. Automated T cell culture
EP3983537A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
AU2020293230A1 (en) 2019-06-12 2022-01-27 Juno Therapeutics, Inc. Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival BCL2 family protein
BR112021025022A2 (pt) 2019-06-12 2022-02-22 Obsidian Therapeutics Inc Composições de ca2 e métodos para regulação ajustáveis
JP2022536975A (ja) 2019-06-21 2022-08-22 カイト ファーマ インコーポレイテッド ＴＧＦ－β受容体及び使用方法
WO2020264019A1 (en) 2019-06-24 2020-12-30 Children's Hospital Los Angeles Bcl11b overexpression to enhance human thymopoiesis and t cell function
JP7295283B2 (ja) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
KR20220031054A (ko) 2019-07-02 2022-03-11 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Egfrviii에 결합하는 단일클론 항체 및 이의 용도
AU2020298572A1 (en) 2019-07-02 2021-11-18 Fred Hutchinson Cancer Center Recombinant Ad35 vectors and related gene therapy improvements
GB201909573D0 (en) 2019-07-03 2019-08-14 Cancer Research Tech Ltd Modulation of T cell cytotoxicity and related therapy
US20220267452A1 (en) 2019-07-12 2022-08-25 Chugai Seiyaku Kabushiki Kaisha Anti-mutation type fgfr3 antibody and use therefor
US20220267726A1 (en) 2019-07-18 2022-08-25 Gpb Scientific, Inc. Ordered processing of blood products to produce therapeutically active cells
WO2021013950A1 (en) 2019-07-23 2021-01-28 Mnemo Therapeutics Immune cells defective for suv39h1
BR112022001194A2 (pt) * 2019-07-24 2022-06-07 Regeneron Pharma Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
KR20220052942A (ko) 2019-07-30 2022-04-28 유니버시티 헬스 네트워크 Mhc 클래스 ii 분자 및 이의 사용 방법
CN110305849B (zh) * 2019-08-01 2021-03-30 广东万海细胞生物科技有限公司 稳定表达car的t细胞及其制备方法与应用
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
BR112022002465A2 (pt) * 2019-08-09 2022-05-03 A2 Biotherapeutics Inc Receptores de superfície celular responsivos à perda de heterozigosidade
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
JP2022545467A (ja) 2019-08-22 2022-10-27 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
JP7723420B2 (ja) * 2019-08-28 2025-08-14 キングス・カレッジ・ロンドン Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤
US12444491B2 (en) 2019-08-30 2025-10-14 Juno Therapeutics, Inc. Machine learning methods for classifying cells
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
EP4025244A1 (en) 2019-09-02 2022-07-13 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
WO2021046143A1 (en) 2019-09-03 2021-03-11 Sana Biotechnology, Inc. Cd24-associated particles and related methods and uses thereof
BR112022003852A2 (pt) 2019-09-03 2022-05-31 Allogene Therapeutics Inc Métodos de preparação de células t para terapia de células t
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
CA3153700A1 (en) 2019-09-09 2021-03-18 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
EP4028413A1 (en) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
US20220347216A1 (en) * 2019-09-13 2022-11-03 Ohio State Innovation Foundation Nk cell immunotherapy compositions, methods of making and methods of using same
US12215105B2 (en) 2019-09-13 2025-02-04 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
US20230127263A1 (en) * 2019-09-20 2023-04-27 The University Of North Carolina At Chapel Hill Modified t cells and methods of preparing the same
CN114401989B (zh) 2019-09-20 2024-02-09 上海吉倍生物技术有限公司 靶向bcma的抗体及嵌合抗原受体
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
KR102685211B1 (ko) * 2019-09-26 2024-07-16 주식회사 헬릭스미스 항-c-Met 항체 또는 그의 항원 결합 단편을 포함하는 키메라 항원 수용체, 및 이의 용도
KR102287180B1 (ko) * 2019-10-01 2021-08-09 충북대학교 산학협력단 Cd138에 특이적으로 결합하는 키메릭 항원 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
AU2020358863A1 (en) 2019-10-03 2022-05-12 Celyntra Therapeutics Sa CRISPR systems with engineered dual guide nucleic acids
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
EP4045083B1 (en) 2019-10-18 2024-01-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
WO2021078910A1 (en) 2019-10-22 2021-04-29 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
EP4048696A1 (en) 2019-10-23 2022-08-31 Kite Pharma, Inc. Anti-idiotypic antigen binding molecules and methods of use thereof
CN110679588A (zh) * 2019-10-23 2020-01-14 厦门生命互联科技有限公司 一种嵌合抗原受体t细胞冻存介质及用途
TWI717880B (zh) * 2019-10-24 2021-02-01 中國醫藥大學附設醫院 Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
CN114929360A (zh) 2019-10-30 2022-08-19 朱诺治疗学有限公司 细胞选择和/或刺激装置及使用方法
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
JP7656830B2 (ja) * 2019-11-01 2025-04-04 京都府公立大学法人 Ｂ細胞抗体受容体、及びその利用
BR112022007548A2 (pt) 2019-11-07 2022-07-12 Juno Therapeutics Inc Combinação de uma terapia de célula t e (s)-3-[4-(4-morfolin-4-ilmetil-benzilóxi)-1-oxo-1,3-di-hidro-isoindol-2-il]-piperidina-2,6-diona
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
BR112022009521A2 (pt) 2019-11-20 2022-08-16 Gi Cell Inc Composição de meio para cultura de células t e método para cultura de células t usando a mesma
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
EP4065158A2 (en) 2019-11-26 2022-10-05 Novartis AG Chimeric antigen receptors binding bcma and cd19 and uses thereof
AR120563A1 (es) 2019-11-26 2022-02-23 Novartis Ag Receptores de antígeno quimérico cd19 y cd22 y sus usos
CN115335399A (zh) 2019-12-06 2022-11-11 朱诺治疗学股份有限公司 针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
US20230028050A1 (en) 2019-12-06 2023-01-26 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
CN115398231A (zh) 2019-12-06 2022-11-25 朱诺治疗学股份有限公司 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法
KR20220145325A (ko) 2019-12-17 2022-10-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
WO2021133920A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
CN117736207A (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
JP7088902B2 (ja) * 2019-12-27 2022-06-21 クレージュ メディカル カンパニー，リミテッド キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球
KR20220129566A (ko) 2019-12-28 2022-09-23 지피비 싸이언티픽, 인크 입자 및 세포를 처리하기 위한 미세 유체 카트리지
JP2023509708A (ja) 2020-01-03 2023-03-09 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
CN113150167A (zh) * 2020-01-22 2021-07-23 中国人民解放军总医院第五医学中心 一种能够反转pd-1免疫抑制信号的car t细胞结构em1设计
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
WO2021150919A1 (en) 2020-01-23 2021-07-29 The Children's Medical Center Corporation Stroma-free t cell differentiation from human pluripotent stem cells
KR20220145341A (ko) 2020-01-24 2022-10-28 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법에서 여포성 림프종 및 변연부 림프종의 투여 및 치료 방법
AU2021211485A1 (en) 2020-01-24 2022-09-15 Regeneron Pharmaceuticals, Inc. Preferentially expressed antigen in melanoma (PRAME) T cell receptors and methods of use thereof
KR20220146480A (ko) 2020-01-28 2022-11-01 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 형질도입 방법
EP4100422A1 (en) 2020-02-03 2022-12-14 MVZ Prof. Niendorf Pathologie Hamburg-West GmbH Marker set for the diagnosis and treatment of cancer
CN115768443A (zh) 2020-02-12 2023-03-07 朱诺治疗学股份有限公司 Cd19定向嵌合抗原受体t细胞组合物和方法及其用途
BR112022015968A2 (pt) 2020-02-12 2022-10-11 Juno Therapeutics Inc Composições de células t do receptor de antígeno quimérico direcionado a bcma e métodos e usos das mesmas
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
IL295297A (en) 2020-02-14 2022-10-01 Univ Johns Hopkins Methods and materials for assessing nucleic acids
EP4107173A1 (en) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
WO2021173995A2 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN115175695A (zh) 2020-02-27 2022-10-11 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
CN111269326A (zh) * 2020-02-28 2020-06-12 南京北恒生物科技有限公司 新型嵌合抗原受体及其用途
US11753403B2 (en) 2020-03-03 2023-09-12 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
WO2022074464A2 (en) 2020-03-05 2022-04-14 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
CA3173981A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of npm1c-positive cancer
EP4117662A4 (en) 2020-03-10 2024-04-03 X4 Pharmaceuticals, Inc. METHODS OF TREATING NEUTROPENIA
KR20240096884A (ko) 2020-03-10 2024-06-26 매사추세츠 인스티튜트 오브 테크놀로지 조작된 기억-유사 nk 세포 및 이의 조성물을 생성하기 위한 방법
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
WO2021188948A1 (en) 2020-03-19 2021-09-23 Kymera Therapeutics, Inc. Mdm2 degraders and uses thereof
JP2023521663A (ja) 2020-03-31 2023-05-25 サナ バイオテクノロジー，インコーポレイテッド 標的化脂質粒子及び組成物ならびにその使用
EP3892720A1 (en) 2020-04-06 2021-10-13 Innovative Cellular Therapeutics Holdings, Ltd. Presenting cell and use thereof in cell therapy
AU2021251265A1 (en) 2020-04-10 2022-11-03 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
US20230340040A1 (en) * 2020-04-14 2023-10-26 St. Jude Children's Research Hospital, Inc. Chimeric myd88 receptors
US12378521B2 (en) 2020-04-15 2025-08-05 Amgen Inc. Method for enhancing production of genetically engineered autologous T cells
US12241086B2 (en) * 2020-04-15 2025-03-04 Amgen Inc. Process for generating genetically engineered autologous T cells
US12359208B2 (en) 2020-04-15 2025-07-15 California Institute Of Technology Thermal control of T-cell immunotherapy through molecular and physical actuation
GB202005599D0 (en) 2020-04-17 2020-06-03 Univ London Modulation of t cell cytotoxicity and related therapy
US20230165872A1 (en) 2020-04-28 2023-06-01 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound
GB202006254D0 (en) 2020-04-28 2020-06-10 Institute Of Cancer Res Anti-cancer vaccines and related therapy
KR20230002554A (ko) 2020-04-28 2023-01-05 아킬레스 테라퓨틱스 유케이 리미티드 T 세포 요법
MX2022013619A (es) 2020-05-01 2022-11-16 Gilead Sciences Inc Compuestos de 2,4-dioxopirimidina que inhiben cd73.
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12497623B2 (en) 2020-05-04 2025-12-16 The Trustees Of The University Of Pennsylvania Non-signaling HIV fusion inhibitors and methods of use thereof
WO2021226063A1 (en) 2020-05-05 2021-11-11 Regeneron Pharmaceuticals, Inc. Car comprising cd28 zeta and cd3 zeta
WO2021228999A1 (en) 2020-05-12 2021-11-18 Institut Curie Neoantigenic epitopes associated with sf3b1 mutations
JP2023526278A (ja) 2020-05-13 2023-06-21 ジュノー セラピューティクス インコーポレイテッド 組み換え受容体を発現しているドナーバッチ細胞を産生するための方法
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
WO2021231954A1 (en) * 2020-05-15 2021-11-18 Precision Biosciences, Inc. Methods for immunotherapy
CA3178726A1 (en) 2020-05-21 2021-11-25 Gregory LIZEE T cell receptors with vgll1 specificity and uses thereof
US20230242643A1 (en) 2020-05-27 2023-08-03 Antion Biosciences Sa Adapter molecules to re-direct car t cells to an antigen of interest
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2021247897A1 (en) 2020-06-03 2021-12-09 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
CN115867294A (zh) 2020-06-04 2023-03-28 凯瑞斯马治疗公司 嵌合抗原受体的新型构建体
WO2021244654A1 (en) * 2020-06-05 2021-12-09 Nanjing Legend Biotech Co., Ltd. Activation induced cytokine production in immune cells
CA3181655A1 (en) 2020-06-08 2021-12-16 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
JP2023530238A (ja) 2020-06-08 2023-07-14 ヤンセン バイオテツク，インコーポレーテツド キメラ抗原発現免疫細胞のインビトロ腫瘍殺傷活性を決定するための細胞ベースのアッセイ
KR20230024967A (ko) 2020-06-11 2023-02-21 노파르티스 아게 Zbtb32 억제제 및 이의 용도
CA3171101A1 (en) * 2020-06-22 2021-12-30 Dina SCHNEIDER Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
WO2021260675A1 (en) 2020-06-24 2021-12-30 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
US20230242678A1 (en) 2020-06-26 2023-08-03 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
KR20230042283A (ko) 2020-06-26 2023-03-28 주노 테라퓨틱스 게엠베하 재조합 수용체를 조건부로 발현하는 조작된 ｔ 세포, 관련된 폴리뉴클레오티드 및 방법
US20230310606A1 (en) 2020-07-17 2023-10-05 Simurx, Inc. Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
KR102297396B1 (ko) 2020-07-29 2021-09-06 (주)티카로스 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
EP4188395A1 (en) 2020-07-30 2023-06-07 Institut Curie Immune cells defective for socs1
CA3189692A1 (en) 2020-07-31 2022-02-03 Leidos, Inc. Lag3 binding peptides
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022029660A1 (en) 2020-08-05 2022-02-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
US20220049226A1 (en) 2020-08-13 2022-02-17 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
JP2023538303A (ja) 2020-08-13 2023-09-07 イェール ユニバーシティー 所望の表現型を有するｃａｒ ｔ細胞の操作および選択のための組成物および方法
US20220047677A1 (en) 2020-08-14 2022-02-17 Kite Pharma, Inc. Immune cell function
KR20230074721A (ko) 2020-08-17 2023-05-31 바이사이클티엑스 리미티드 Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
IL300500A (en) 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Preparations and methods for the treatment of mesothelin positive cancer
MX2023002017A (es) 2020-08-20 2023-04-28 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para ceacam.
MX2023002107A (es) 2020-08-21 2023-03-15 Novartis Ag Composiciones y metodos para la generacion in vivo de celulas que expresan car.
JP2023538647A (ja) 2020-08-21 2023-09-08 １２３４３０９６ カナダ インク． モジュール型アセンブリ受容体およびその使用
EP4501951A3 (en) 2020-08-25 2025-04-30 Kite Pharma, Inc. T cells with improved functionality
WO2022046840A1 (en) * 2020-08-26 2022-03-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Hybrid allosteric receptor-engineered stem cells
CA3198203A1 (en) 2020-10-12 2022-04-21 Leidos, Inc. Immunomodulatory peptides
EP4228648A4 (en) * 2020-10-16 2024-12-11 Neonc Technologies, Inc. COMBINATION OF POH AND REMDESIVIR FOR THE TREATMENT OF CNS INFECTIONS
IL302276A (en) 2020-10-23 2023-06-01 Asher Biotherapeutics Inc Fusions with cd8 antigen binding molecules for modulating immune cell function
CN116528879A (zh) 2020-10-28 2023-08-01 凯德药业股份有限公司 用于表征t细胞杂质的流式细胞术方法
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
CN116635062A (zh) 2020-11-13 2023-08-22 诺华股份有限公司 使用表达嵌合抗原受体（car）的细胞的组合疗法
CN112195250A (zh) * 2020-11-20 2021-01-08 山东省医学科学院附属医院 一种qPCR试剂盒及应用
EP4251742A4 (en) 2020-11-24 2025-01-08 Lyell Immunopharma, Inc. METHODS OF MAKING, COMPOSITIONS COMPRISING, AND METHODS OF USING REGENERATED T CELLS
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CA3201621A1 (en) 2020-12-03 2022-06-09 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
EP4267623A1 (en) 2020-12-24 2023-11-01 Kite Pharma, Inc. Prostate cancer chimeric antigen receptors
TW202242117A (zh) 2020-12-30 2022-11-01 美商亞勞諾斯醫療公司 包含多順反子表現卡匣之重組載體及其使用方法
AR124547A1 (es) 2020-12-30 2023-04-05 Kymera Therapeutics Inc Degradadores de irak y sus usos
IL303473A (en) 2020-12-31 2023-08-01 Sana Biotechnology Inc Methods and compositions for modulating car-t activity
JP2024502618A (ja) 2021-01-08 2024-01-22 セラノーム， インコーポレイテッド 生体試料を分析するためのデバイスおよび方法
WO2022150582A1 (en) 2021-01-10 2022-07-14 Kite Pharma, Inc. T cell therapy
JP2024503027A (ja) 2021-01-11 2024-01-24 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ８標的ウイルスベクターの使用方法
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
US20240317890A1 (en) 2021-01-14 2024-09-26 Institut Curie Her2 single domain antibodies variants and cars thereof
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN117062611A (zh) 2021-01-26 2023-11-14 惠和生物技术(上海)有限公司 嵌合抗原受体（car）构建体和表达car构建体的nk细胞
CA3209218A1 (en) * 2021-01-27 2022-08-04 H. Lee Moffitt Cancer Center And Research Institute Inc. Bi-specific car t cells for b cell malignancies
KR20230135593A (ko) 2021-01-28 2023-09-25 알로젠 테라퓨틱스 인코포레이티드 면역 세포를 형질도입하는 방법
HRP20250696T1 (hr) 2021-01-28 2025-08-01 Regeneron Pharmaceuticals, Inc. Sastavi i postupci za liječenje sindroma oslobađanja citokina
US12378229B2 (en) 2021-02-02 2025-08-05 Liminal Biosciences Limited GPR84 antagonists and uses thereof
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
US11773103B2 (en) 2021-02-15 2023-10-03 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
MX2023009527A (es) 2021-02-15 2023-08-24 Kymera Therapeutics Inc Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
US20220265719A1 (en) 2021-02-20 2022-08-25 Kite Pharma, Inc. Immunotherapies
CA3209863A1 (en) 2021-02-25 2022-09-01 Andrea BARGHETTI Compositions and methods for targeting, editing, or modifying genes
KR20230165771A (ko) 2021-03-03 2023-12-05 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법 및 dgk 억제제의 조합
CA3212530A1 (en) 2021-03-05 2022-09-09 Shanghai GenBase Biotechnology Co., Ltd. Anti-cldn6 antibody and use thereof
EP4301756A4 (en) 2021-03-05 2025-02-26 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND THEIR USES
US12454563B2 (en) 2021-03-11 2025-10-28 Kite Pharma, Inc. Immune cell function
JP2024510217A (ja) 2021-03-11 2024-03-06 アンスティテュ・クリー 膜貫通ネオ抗原ペプチド
AU2022235060A1 (en) 2021-03-11 2023-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Tumor neoantigenic peptides and uses thereof
US20250302929A1 (en) 2021-03-11 2025-10-02 Institut Curie Tumor neoantigenic peptides
US20240150472A1 (en) 2021-03-17 2024-05-09 Daiichi Sankyo Company, Limited Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody
KR20230159851A (ko) 2021-03-22 2023-11-22 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 결정하는 방법
AU2022244229A1 (en) 2021-03-22 2023-09-14 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
EP4313083A4 (en) 2021-03-26 2025-06-18 Arcellx, Inc. MULTIFUNCTIONAL IMMUNE CELL THERAPIES
IL307257A (en) 2021-03-29 2023-11-01 Juno Therapeutics Inc A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma
JP2024514245A (ja) 2021-03-29 2024-03-29 ジュノー セラピューティクス インコーポレイテッド チェックポイント阻害剤療法とｃａｒ ｔ細胞療法との組合せを用いた投薬および処置のための方法
US12071442B2 (en) 2021-03-29 2024-08-27 Nimbus Saturn, Inc. Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
BR112023020781A2 (pt) 2021-04-09 2023-12-19 Nimbus Clio Inc Moduladores de cbl-b e usos dos mesmos
WO2022214835A1 (en) 2021-04-09 2022-10-13 Achilles Therapeutics Uk Limited Batch release assay for pharmaceutical products relating to t cell therapies
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
EP4323943A1 (en) 2021-04-16 2024-02-21 Kite Pharma, Inc. Methods and systems for scheduling a patient-specific immunotherapy procedure
IL307384A (en) 2021-04-16 2023-11-01 Kite Pharma Inc Molecules with a dual link to TACI and BCMA
CN117529333A (zh) 2021-04-16 2024-02-06 细胞基因公司 对先前进行过干细胞移植的患者的t细胞疗法
EP4323066A1 (en) 2021-04-16 2024-02-21 Ikena Oncology, Inc. Mek inhibitors and uses thereof
JP2024514163A (ja) 2021-04-16 2024-03-28 セルジーン コーポレーション Ｂｃｍａ指向性ｔ細胞療法を用いた併用療法
EP4326293A4 (en) 2021-04-22 2025-03-12 Baylor College of Medicine METHODS FOR MODIFYING IMMUNE CELLS HAVING REDUCED FRATRICIDAL ACTIVITY
WO2022226355A2 (en) * 2021-04-23 2022-10-27 Myeloid Therapeutics, Inc. Compositions and methods for conditioning patients for cell therapy
EP4330381A1 (en) 2021-04-27 2024-03-06 Novartis AG Viral vector production system
AR125461A1 (es) 2021-04-27 2023-07-19 Takeda Pharmaceuticals Co Células presentadoras de antígeno recombinante
KR20240005854A (ko) 2021-05-04 2024-01-12 리제너론 파아마슈티컬스, 인크. Mage-a4 특이성을 갖는 키메라 항원 수용체 및 이들의 용도
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
AR125798A1 (es) 2021-05-07 2023-08-16 Kymera Therapeutics Inc Degradadores cdk2 y usos de los mismos
KR20230173179A (ko) 2021-05-14 2023-12-26 카이트 파마 인코포레이티드 키메라 항원 수용체 t세포 요법
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
AU2022277931A1 (en) 2021-05-19 2023-11-30 Sana Biotechnology, Inc. Hypoimmunogenic rhd negative primary t cells
CN117677633A (zh) 2021-05-24 2024-03-08 凯德药业股份有限公司 基于nkg2d的嵌合抗原受体
US20240238298A1 (en) * 2021-05-26 2024-07-18 Emory University JAK Inhibitors for Managing Conditions in Patients with Down's Syndrome or Other Trisomy
CA3216346A1 (en) 2021-05-27 2022-12-01 Edward Rebar Hypoimmunogenic cells comprising engineered hla-e or hla-g
AU2022280957A1 (en) 2021-05-28 2023-11-30 Sana Biotechnology, Inc. Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
EP4419672A2 (en) 2021-06-01 2024-08-28 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
AU2022288058A1 (en) 2021-06-07 2023-11-16 Agonox, Inc. Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
KR20240019811A (ko) 2021-06-08 2024-02-14 카이트 파마 인코포레이티드 Gpc3 결합 분자
EP4370676A2 (en) 2021-06-18 2024-05-22 Artisan Development Labs, Inc. Compositions and methods for targeting, editing or modifying human genes
JP2024524185A (ja) 2021-06-22 2024-07-05 アキレス セラピューティクス ユーケー リミテッド 抗原特異的ｔ細胞を生成するための方法
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
CN117480155A (zh) 2021-06-23 2024-01-30 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023278811A1 (en) 2021-07-01 2023-01-05 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
EP4363558A1 (en) 2021-07-01 2024-05-08 Kite Pharma, Inc. Closed-system and method for autologous and allogeneic cell therapy manufacturing
JP2024525485A (ja) 2021-07-02 2024-07-12 カイト ファーマ インコーポレイテッド 細胞療法適用において使用される遺伝子構築物由来の遺伝子産物におけるバリアントを特定するための方法
US20240368145A1 (en) 2021-07-09 2024-11-07 Immunic Ag Methods for treating cancer
CA3225283A1 (en) 2021-07-14 2023-01-19 Sonja SCHREPFER Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
JP2024525789A (ja) * 2021-07-16 2024-07-12 サナ バイオテクノロジー，インコーポレイテッド 細胞ベースの療法のためのポリシストロニックベクター
US20240325534A1 (en) * 2021-07-19 2024-10-03 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor (car)-t signaling optimization for tuning antigen activation threshold
US20230190799A1 (en) * 2021-07-21 2023-06-22 City Of Hope Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
US20230268031A1 (en) 2021-07-30 2023-08-24 Kite Pharma, Inc. Monitoring and management of cell therapy-induced toxicities
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
CA3228262A1 (en) 2021-08-04 2023-02-09 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
WO2023019128A1 (en) * 2021-08-09 2023-02-16 The Trustees Of The University Of Pennyslvania Optimizing t cell differentiation state with micrornas
CA3227613A1 (en) 2021-08-11 2023-02-16 William Dowdle Inducible systems for altering gene expression in hypoimmunogenic cells
US20240425820A1 (en) 2021-08-11 2024-12-26 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
AU2022325232A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
EP4384193A2 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
JP2024534772A (ja) 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド 同種異系細胞療法用の遺伝子改変細胞
US20250295693A1 (en) 2021-08-18 2025-09-25 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
TW202323521A (zh) 2021-08-20 2023-06-16 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
JP2024531446A (ja) 2021-08-24 2024-08-29 エコール ポリテクニーク フェデラル デ ローザンヌ （イーピーエフエル） 癌免疫療法の増強のためのｉｌ－１０発現細胞
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
KR20240069799A (ko) 2021-09-27 2024-05-20 소티오 바이오테크 인크. 해당과정 경로 밖으로 포도당 대사산물을 재지향시키는 트랜스 대사 분자와 조합되는 키메라 수용체 폴리펩타이드 및 이의 치료적 용도
EP4416292A2 (en) 2021-10-14 2024-08-21 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
AR127745A1 (es) 2021-10-18 2024-02-28 Kite Pharma Inc Dominios de señalización para receptores quiméricos de antígenos
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
EP4422635A4 (en) 2021-10-29 2025-11-26 Kymera Therapeutics Inc IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
JP2024540320A (ja) 2021-11-03 2024-10-31 セルジーン コーポレーション 骨髄腫を処置する際に使用するための、ｂ細胞成熟抗原に特異的なキメラ抗原受容体
JP2024545363A (ja) 2021-11-16 2024-12-05 ソティオ・バイオテック・インコーポレイテッド 粘液型／円形細胞型脂肪肉腫患者の治療
WO2023092119A2 (en) 2021-11-22 2023-05-25 Ludwig Institute For Cancer Research Ltd Methods for predicting responsiveness to a cancer therapy
US20250354167A1 (en) 2021-12-09 2025-11-20 Zygosity Limited Vector
WO2023115039A2 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
US20240408192A1 (en) 2021-12-17 2024-12-12 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR102809807B1 (ko) * 2021-12-21 2025-05-16 한림대학교 산학협력단 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
MX2024007528A (es) 2021-12-23 2024-08-30 Sana Biotechnology Inc Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados.
EP4456910A1 (en) 2021-12-28 2024-11-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
AR128124A1 (es) 2021-12-30 2024-03-27 Tr1X Inc Células t cd4⁺ que expresan il-10 y receptores de antígenos quiméricos y usos de estos
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
TW202340474A (zh) 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途
CA3247928A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
CA3247927A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
US20230227779A1 (en) 2022-01-19 2023-07-20 Innovative Cellular Therapeutics Holdings, Ltd. Enhanced Chimeric Antigen Receptor Cells in Hypoxic Tumor Microenvironment
CN120077132A (zh) 2022-01-21 2025-05-30 姆内莫治疗公司 Rna对suv39h1表达的调控
JP2025504002A (ja) 2022-01-28 2025-02-06 ジュノー セラピューティクス インコーポレイテッド 細胞組成物を製造する方法
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CA3243560A1 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Iraqi Degradation Agents and Their Uses
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
WO2023150181A1 (en) 2022-02-01 2023-08-10 President And Fellows Of Harvard College Methods and compositions for treating cancer
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
JP2025508371A (ja) * 2022-02-11 2025-03-26 フレッド ハッチンソン キャンサー センター Ｓｔｅａｐ１に結合するキメラ抗原受容体
US20250302953A1 (en) 2022-02-14 2025-10-02 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
IL314451A (en) 2022-02-15 2024-09-01 Kite Pharma Inc Predicting adverse events from immunotherapy
IL315000A (en) 2022-02-17 2024-10-01 Sana Biotechnology Inc Engineered cd47 proteins and uses thereof
CN119031931A (zh) 2022-02-22 2024-11-26 朱诺治疗学股份有限公司 蛋白酶3（pr3）嵌合自身抗体受体t细胞及相关方法和用途
TW202340457A (zh) 2022-02-28 2023-10-16 美商凱特製藥公司 同種異體治療細胞
WO2023167882A1 (en) 2022-03-01 2023-09-07 Artisan Development Labs, Inc. Composition and methods for transgene insertion
EP4490173A1 (en) 2022-03-07 2025-01-15 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
CN119156403A (zh) 2022-03-08 2024-12-17 阿伦蒂斯治疗股份公司 抗紧密连接蛋白-1抗体增加t细胞可用性的用途
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US20250228940A1 (en) 2022-03-11 2025-07-17 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
US20250101382A1 (en) 2022-03-11 2025-03-27 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
WO2023178348A1 (en) 2022-03-18 2023-09-21 The Regents Of The University Of Colorado, A Body Corporate Genetically engineered t-cell co-receptors and methods of use thereof
CA3254182A1 (en) 2022-03-24 2023-09-28 Universite Paris Cite Immunotherapy targeting neoantigenic peptides derived from a tumor-specific transposable element in a glioblastoma
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
GB202204386D0 (en) 2022-03-28 2022-05-11 Cambridge Entpr Ltd Engineered immune cell platform
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023196921A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Granzyme expressing t cells and methods of use
WO2023196933A1 (en) 2022-04-06 2023-10-12 The Regents Of The University Of Colorado, A Body Corporate Chimeric antigen receptor t cells and methods of use thereof
PE20250157A1 (es) 2022-04-21 2025-01-22 Gilead Sciences Inc Compuestos de modulacion de kras g12d
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
EP4514382A1 (en) 2022-04-28 2025-03-05 Musc Foundation for Research Development Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023220644A1 (en) 2022-05-10 2023-11-16 Yale University Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
EP4522183A2 (en) 2022-05-11 2025-03-19 Celgene Corporation Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
IL316768A (en) 2022-05-25 2025-01-01 Ikena Oncology Inc MEK inhibitors and their uses
CN119173527A (zh) 2022-05-27 2024-12-20 凯德药业股份有限公司 细胞疗法构建体的非病毒递送
WO2023230276A1 (en) 2022-05-27 2023-11-30 Kite Pharma, Inc. Compositions and methods for preparing engineered lymphocytes for cell therapy
EP4536812A1 (en) 2022-06-09 2025-04-16 Kite Pharma, Inc. Methods of preparing lymphocytes for cell therapy
IL317568A (en) 2022-06-10 2025-02-01 Res Found Dev Engineered FCRIIB Selective IgG1 FC Variants, and Their Uses
WO2023242343A1 (en) 2022-06-15 2023-12-21 Immunoscape Pte. Ltd. Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof
EP4543923A1 (en) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024006960A1 (en) 2022-06-29 2024-01-04 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
CA3259982A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
CN119384415A (zh) 2022-07-01 2025-01-28 吉利德科学公司 Cd73化合物
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
CN119923410A (zh) 2022-07-28 2025-05-02 莱蒂恩技术公司 用于治疗实体瘤的嵌合抗原受体治疗
IL318577A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES
JP2025525845A (ja) 2022-08-02 2025-08-07 国立大学法人北海道大学 オルガネラ複合体による細胞療法を改善する方法
IL318575A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF
JP2025527248A (ja) 2022-08-02 2025-08-20 リミナル・バイオサイエンシーズ・リミテッド 置換ピリドンｇｐｒ８４アンタゴニスト及びその使用
CN119816590A (zh) 2022-08-10 2025-04-11 武田药品工业株式会社 低免疫原性的经修饰细胞
EP4572787A1 (en) 2022-08-19 2025-06-25 SOTIO Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
CN120435310A (zh) 2022-08-26 2025-08-05 朱诺治疗学股份有限公司 对δ样配体3（DLL3）具有特异性的抗体和嵌合抗原受体
EP4577234A1 (en) 2022-08-26 2025-07-02 Kite Pharma, Inc. Improving immune cell function
CN120152717A (zh) 2022-09-08 2025-06-13 朱诺治疗学股份有限公司 T细胞疗法和连续或间歇dgk抑制剂给药的组合
KR20250067174A (ko) 2022-09-15 2025-05-14 노파르티스 아게 키메라 항원 수용체 요법을 사용한 자가면역 장애의 치료
CA3268005A1 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems and methods of T lymphocyte function modulation
CN116063560A (zh) * 2022-09-21 2023-05-05 东莞市东南部中心医院 一种sh Blimp-1 CAR-T细胞的构建及应用
WO2024064824A2 (en) 2022-09-21 2024-03-28 Yale University Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
IL319598A (en) 2022-09-30 2025-05-01 Caribou Biosciences Inc Anti-ROR1 chimeric antigen receptors, CAR-NK cells and related methods
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
EP4608987A1 (en) 2022-10-28 2025-09-03 Kite Pharma, Inc. Factors for optimizing immunotherapy
EP4608416A1 (en) 2022-10-28 2025-09-03 Kite Pharma, Inc. Expedited administration of engineered lymphocytes
WO2024091669A1 (en) 2022-10-28 2024-05-02 Ginkgo Bioworks, Inc. Chimeric antigen receptors comprising an intracellular domain pair
US20240165160A1 (en) 2022-10-28 2024-05-23 Kite Pharma, Inc. Efficacy and durable response of immunotherapy
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024097315A2 (en) 2022-11-02 2024-05-10 Sana Biotechnology, Inc. Cell therapy products and methods for producing same
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP4615960A1 (en) 2022-11-09 2025-09-17 C3S2 GmbH Methods for manufacturing engineered immune cells
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
US20250332196A1 (en) 2022-11-14 2025-10-30 Caribou Biosciences, Inc. Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
CN120548323A (zh) 2022-11-18 2025-08-26 首尔国立大学校产学协力团 利用ctla-4变体及嵌合抗原受体的双基因转导免疫细胞及其用途
AR131141A1 (es) 2022-11-22 2025-02-19 Pic Therapeutics Inc Inhibidores de eif4e y usos de los mismos
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
WO2024119074A1 (en) 2022-12-01 2024-06-06 Generation Bio Co. Stealth lipid nanoparticle compositions for cell targeting
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
KR20250121074A (ko) 2022-12-09 2025-08-11 주노 쎄러퓨티크스 인코퍼레이티드 홀로그래픽 이미징을 사용하여 세포 표현형을 예측하기 위한 기계 학습 방법
AR131320A1 (es) 2022-12-13 2025-03-05 Juno Therapeutics Inc Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
US20240254118A1 (en) 2022-12-22 2024-08-01 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024155821A1 (en) 2023-01-18 2024-07-25 Yale University Chimeric antigen receptors (car) with intrinsically disordered regions and methods of use thereof
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
WO2024178128A1 (en) * 2023-02-22 2024-08-29 Elysion Therapeutics, Inc. Lysis sensing receptors and uses thereof
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
AU2024230609A1 (en) 2023-02-28 2025-09-04 Juno Therapeutics, Inc. Cell therapy for treating systemic autoimmune diseases
WO2024182539A1 (en) 2023-02-28 2024-09-06 Lyell Immunopharma, Inc. Methods of culturing reprogrammed cells
AU2024233625A1 (en) 2023-03-03 2025-09-18 Arsenal Biosciences, Inc. Systems targeting psma and ca9
CN120769864A (zh) 2023-03-09 2025-10-10 凯德药业股份有限公司 抗原结合分子和使用方法
WO2024192100A1 (en) 2023-03-13 2024-09-19 Arsenal Biosciences, Inc. Synthetic pathway activators
WO2024196689A1 (en) 2023-03-17 2024-09-26 Kite Pharma, Inc. Impact of tumor microenvironment on efficacy of immunotherapy
WO2024194471A1 (en) 2023-03-23 2024-09-26 Alentis Therapeutics Ag Biomarker for cancer treatment using anti-claudin-1 antibodies
WO2024206155A1 (en) 2023-03-24 2024-10-03 Cornell University Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
CN120641113A (zh) 2023-03-31 2025-09-12 西比曼生物科技集团 靶向cd20和bcma的双特异性嵌合抗原受体
WO2024211478A1 (en) 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a lymphotoxin beta receptor agonist
WO2024211852A1 (en) * 2023-04-07 2024-10-10 Fate Therapeutics, Inc. Ipsc-derived nk cell for lymphoma treatment
KR20250167002A (ko) 2023-04-11 2025-11-28 길리애드 사이언시즈, 인코포레이티드 Kras 조절 화합물
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
WO2024220598A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Lentiviral vectors with two or more genomes
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
KR20250169631A (ko) 2023-04-18 2025-12-03 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
WO2024220619A1 (en) 2023-04-21 2024-10-24 Kite Pharma, Inc. Allogenic therapeutic cells with reduced risk of immune rejection
CN121079300A (zh) 2023-04-21 2025-12-05 吉利德科学公司 Prmt5抑制剂及其用途
CN121038806A (zh) 2023-04-25 2025-11-28 阿森纳生物科学公司 用于转录调控的新颖受体
WO2024226858A1 (en) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Methods for viral vector manufacturing
WO2024226829A2 (en) 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
AU2024263914A1 (en) 2023-04-27 2025-12-04 Takeda Pharmaceutical Company Limited Method for expanding cd56+/cd3- cells
AU2024264056A1 (en) 2023-04-28 2025-11-20 Shenzhen Shenxin Biotechnology Co., Ltd. Modified delivery vector and use thereof
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
AU2024267555A1 (en) 2023-05-11 2025-11-20 Alaya.Bio Inc. Extracellular vesicles for the delivery of payloads to eukaryotic cells
WO2024238656A1 (en) 2023-05-15 2024-11-21 Yale Univeristy Chimeric antigen receptor compositions, car-mast cells formed therefrom, and methods of use thereof
WO2024238903A1 (en) * 2023-05-17 2024-11-21 Mayo Foundation For Medical Education And Research Materials and methods for increasing immune responses within a mammal
WO2024236547A1 (en) 2023-05-18 2024-11-21 Inceptor Bio, Llc Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2024243365A2 (en) 2023-05-23 2024-11-28 Juno Therapeutics, Inc. Activation markers of t cells and method for assessing t cell activation
CN120981456A (zh) 2023-05-24 2025-11-18 金橘生物科技公司 杂环化合物及其用途
WO2024243511A1 (en) 2023-05-25 2024-11-28 Regeneron Pharmaceuticals, Inc. T cell receptors that bind presented hpv16-, mart1-, cmv-, ebv-, or influenza- peptides
WO2024243514A1 (en) * 2023-05-25 2024-11-28 Trustees Of Dartmouth College Leveraging photothermal heating for surface processing of active agents
WO2024259376A2 (en) 2023-06-14 2024-12-19 Arsenal Biosciences, Inc. Non-viral cell engineering
EP4620470A3 (en) 2023-06-23 2025-10-08 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2025007073A2 (en) 2023-06-29 2025-01-02 Dispatch Biotherapeutics, Inc. Synthetic cytokine receptors
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
WO2025038750A2 (en) 2023-08-14 2025-02-20 President And Fellows Of Harvard College Methods and compositions for treating cancer
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
WO2025051339A1 (en) 2023-09-05 2025-03-13 Tiber Biotech Srl SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR
WO2025054202A1 (en) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Method of screening a sample comprising a transgene with a unique barcode
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
US20250090662A1 (en) * 2023-09-15 2025-03-20 Singular Immune, Inc. Composition and method of use recombinant fusion protein to generate car-immune cells
WO2025068803A1 (en) 2023-09-26 2025-04-03 Astrazeneca Ab Therapeutic combinations comprising anti-steap2 chimeric antigen receptor t cells
WO2025072571A1 (en) 2023-09-27 2025-04-03 Cellanome, Inc. Cell culture within microfluidic structures
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025083398A1 (en) 2023-10-16 2025-04-24 Cell Therapy Catapult Limited Co-culture
WO2025082603A1 (en) 2023-10-18 2025-04-24 Institut Curie Engineered immune cells overexpressing cd74 molecule
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025090985A1 (en) * 2023-10-27 2025-05-01 Duke University Compositions comprising chimeric antigen receptors targeting citrullinated vimentin and methods of use thereof
WO2025096594A2 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof
WO2025096305A1 (en) * 2023-10-30 2025-05-08 The Cleveland Clinic Foundation Chimeric antigen receptors with a tip co-stimulatory domain
WO2025096419A1 (en) 2023-10-31 2025-05-08 Lyell Immunopharma, Inc. T cells comprising a chimeric antigen receptor targeting transforming growth factor beta and a t cell receptor targeting a tumor antigen, and use thereof
US20250161361A1 (en) 2023-11-01 2025-05-22 Kite Pharma, Inc. Factors for optimizing immunotherapy efficacy
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025096975A1 (en) 2023-11-02 2025-05-08 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of enhancing immune cell therapies by runx2 modulation
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025128434A1 (en) 2023-12-14 2025-06-19 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of ven/aza resistant acute myeloid leukemia
WO2025129120A2 (en) 2023-12-15 2025-06-19 Port Therapeutics, Inc. Use of thermal bioswitches for treating autoimmune diseases
TW202526007A (zh) 2023-12-21 2025-07-01 美商凱特製藥公司 用於上調低密度脂蛋白受體（ｌｄｌ－ｒ）表現之系統及方法
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025146286A1 (en) 2024-01-04 2025-07-10 Immunoscape Pte. Ltd. Human t cell receptors and uses thereof
WO2025151838A1 (en) 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Safety switches to control in vitro and in vivo proliferation of cell therapy products
WO2025151923A1 (en) * 2024-01-17 2025-07-24 Newsouth Innovations Pty Limited Apparatus for production of engineered cells
WO2025158400A1 (en) 2024-01-24 2025-07-31 Yale University Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy
WO2025163107A1 (en) 2024-02-01 2025-08-07 Institut Gustave Roussy Immune cells defective for znf217 and uses thereof
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US20250297219A1 (en) 2024-02-08 2025-09-25 Kite Pharma, Inc. Methods for generating engineered lymphocytes with enriched t memory stem cells
US20250262300A1 (en) 2024-02-16 2025-08-21 Kite Pharma, Inc. Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
WO2025181329A1 (en) 2024-03-01 2025-09-04 Immunoscape Pte. Ltd. Human t cell receptors and uses thereof
WO2025188561A1 (en) 2024-03-04 2025-09-12 Kite Pharma, Inc. Predictive markers for immunotherapy
WO2025191300A1 (en) 2024-03-12 2025-09-18 Novartis Ag Rapcabtagene autoleucel for use in treating systemic lupus erythematosus
US20250361297A1 (en) 2024-03-12 2025-11-27 Adaptam Therapeutics, S.L. Anti- siglec-15 binding molecules and methods of use
WO2025191531A1 (en) 2024-03-15 2025-09-18 Takeda Pharmaceutical Company Limited Cd19 targeting car nk cells in treating systemic lupus erythematosus and lupus nephritis
WO2025199346A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Antigen binding proteins that bind tmprss4 and methods of use thereof
US20250297255A1 (en) 2024-03-20 2025-09-25 Arsenal Biosciences, Inc. Systems targeting tmprss4 and slc34a2
EP4624494A1 (en) 2024-03-29 2025-10-01 Institut Curie Her2 single domain antibody and uses thereof
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025231376A1 (en) 2024-05-03 2025-11-06 Kite Pharma, Inc. Chimeric receptors binding to cll-1 and methods of use thereof
WO2025235851A1 (en) 2024-05-10 2025-11-13 Juno Therapeutics, Inc. Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025250011A1 (en) 2024-05-29 2025-12-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment for cancer
WO2025250819A1 (en) 2024-05-31 2025-12-04 Kite Pharma, Inc. Tricistronic constructs for anti-gpc3 car
WO2025255030A1 (en) 2024-06-03 2025-12-11 Cornell University Interferon gamma responsive chimeric t cell costimulatory receptor
WO2025259108A1 (en) 2024-06-11 2025-12-18 Prinses Máxima Centrum Voor Kinderoncologie B.V. Brain organoid
WO2025259578A1 (en) 2024-06-11 2025-12-18 Kite Pharma, Inc. Methods for generating engineered lymphocytes

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US4882282A (en) * 1985-08-16 1989-11-21 Immunex Corporation DNA sequences encoding bovine interleukin-2
US5906936A (en) 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
IL101147A (en) 1991-03-07 2004-06-20 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
AU697482B2 (en) * 1993-09-16 1998-10-08 Indiana University Research And Technology Corporation Human receptor H4-1BB
EP0758394B1 (en) 1994-05-02 2002-11-20 Bernd Groner Bifunctional protein, preparation and use
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
CA2209300C (en) 1995-02-24 2011-06-28 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5874240A (en) 1996-03-15 1999-02-23 Human Genome Sciences, Inc. Human 4-1BB receptor splicing variant
CA2269738A1 (en) 1996-10-25 1998-05-07 Mitchell H. Finer Targeted cytolysis of cancer cells
US20030060444A1 (en) 1997-06-25 2003-03-27 Celltech Therapeutics, Ltd. Cell activation process and reagents therefor
GB9713473D0 (en) 1997-06-25 1997-09-03 Celltech Therapeutics Ltd Biological products
GB9722779D0 (en) * 1997-10-28 1997-12-24 Isis Innovation Human CD8 as an inhibitor of the cellular immune system
AU748143B2 (en) * 1997-10-28 2002-05-30 University Of British Columbia, The Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
AU4418900A (en) 1999-04-16 2000-11-02 Celltech Therapeutics Limited Synthetic transmembrane components
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9925848D0 (en) 1999-11-01 1999-12-29 Celltech Therapeutics Ltd Biological products
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
EP1230394A4 (en) 1999-11-10 2002-12-18 Uab Research Foundation VECTOR TRANSDUCTION OF HEMATOPOIETIC STEM CELLS BY LENTIVIRUS
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
AU4328801A (en) 2000-02-24 2001-09-03 Xcyte Therapies Inc Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
IL136511A0 (en) * 2000-06-01 2001-06-14 Gavish Galilee Bio Appl Ltd Genetically engineered mhc molecules
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
ATE338124T1 (de) * 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) * 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
JP4448282B2 (ja) 2001-04-30 2010-04-07 シティ・オブ・ホープ ヒト癌を処置するのに有用なキメライムノレセプター
US20090257994A1 (en) * 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
JP3878522B2 (ja) * 2002-07-18 2007-02-07 株式会社日立製作所 ベンチュリ式燃料供給装置を備えたエンジンの空燃比制御方法及びその方法を備えた燃料制御装置
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US7402431B2 (en) * 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US8198020B2 (en) 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP1765988B1 (en) 2004-05-27 2017-09-20 The Trustees of The University of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
EP3530321A1 (en) 2004-12-10 2019-08-28 Peter MacCallum Cancer Institute Methods and compositions for adoptive immunotherapy
US7581948B2 (en) * 2005-12-21 2009-09-01 Johns Manville Burner apparatus and methods for making inorganic fibers
US7551486B2 (en) * 2006-05-15 2009-06-23 Apple Inc. Iterative memory cell charging based on reference cell value
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
EP1916259A1 (en) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
US20080311098A1 (en) * 2007-02-14 2008-12-18 Lapointe Rejean Compounds and methods for modulating the immune response against antigens
US7448191B2 (en) * 2007-02-14 2008-11-11 Deere & Company Mower deck lift system with transport lock
CA2584494A1 (en) * 2007-03-27 2008-09-27 Jeffrey A. Medin Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
EP2856876B1 (en) 2007-03-30 2018-01-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
WO2009091826A2 (en) * 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
DK2279253T3 (en) * 2008-04-09 2017-02-13 Maxcyte Inc Construction and application of therapeutic compositions of freshly isolated cells
US8822647B2 (en) 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
CN101348525B (zh) * 2008-08-28 2011-11-16 南京医科大学 抗血吸虫单克隆抗体np11-4单链抗体及其制备方法、应用
WO2010085660A2 (en) * 2009-01-23 2010-07-29 Roger Williams Hospital Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
WO2010095031A2 (en) * 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
EP3467101A3 (en) 2010-09-08 2019-06-19 Baylor College of Medicine Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells
WO2012058460A2 (en) 2010-10-27 2012-05-03 Baylor College Of Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2651442B1 (en) 2010-12-14 2020-04-22 University of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
EA201391449A1 (ru) 2011-04-01 2014-03-31 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела против пептидов цитозоля
ES2649967T3 (es) 2011-04-08 2018-01-16 Baylor College Of Medicine Inversión de los efectos del microentorno tumoral utilizando receptores quiméricos de citocinas
US20130071414A1 (en) 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
US20140255363A1 (en) 2011-09-16 2014-09-11 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
US9868774B2 (en) 2011-10-20 2018-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD22 chimeric antigen receptors

Also Published As

Publication number Publication date
EP3305798A1 (en) 2018-04-11
JP2016174607A (ja) 2016-10-06
SG10201510092QA (en) 2016-01-28
CY2019007I1 (el) 2019-11-27
NO2019007I1 (no) 2019-02-15
CN107699585A (zh) 2018-02-16
BR112013014265B1 (pt) 2023-05-16
GT201300150A (es) 2014-06-10
JP2020022456A (ja) 2020-02-13
CR20130269A (es) 2013-09-03
AU2020200767B2 (en) 2021-12-23
US9102761B2 (en) 2015-08-11
LUC00104I2 (enExample) 2019-12-27
MX347078B (es) 2017-04-10
HUE042207T2 (hu) 2019-06-28
MX385933B (es) 2025-03-18
SI2649086T1 (en) 2018-01-31
IL226694B (en) 2020-10-29
BR112013014265A2 (pt) 2017-12-19
PT2649086T (pt) 2017-10-19
KR102062407B1 (ko) 2020-01-03
ZA201304470B (en) 2014-08-27
CN108103085B (zh) 2024-10-08
US20150093822A1 (en) 2015-04-02
WO2012079000A4 (en) 2012-08-23
JP2024056708A (ja) 2024-04-23
KR20210059762A (ko) 2021-05-25
RS56453B1 (sr) 2018-01-31
CY2019008I1 (el) 2019-11-27
JP6943933B2 (ja) 2021-10-06
CA2820681C (en) 2018-10-23
AP2013006918A0 (en) 2013-06-30
EP2649086A4 (en) 2014-12-31
US20130288368A1 (en) 2013-10-31
JP6588060B2 (ja) 2019-10-09
KR20230133410A (ko) 2023-09-19
EA027153B1 (ru) 2017-06-30
US9102760B2 (en) 2015-08-11
CO6801633A2 (es) 2013-11-29
HK1253052A1 (en) 2019-06-06
US9328156B2 (en) 2016-05-03
US8911993B2 (en) 2014-12-16
CN110452882A (zh) 2019-11-15
AU2017203087B2 (en) 2019-06-20
US20170283775A1 (en) 2017-10-05
NL300967I2 (nl) 2019-08-20
US9518123B2 (en) 2016-12-13
BR112013014265A8 (pt) 2018-04-17
AU2020200767C1 (en) 2025-04-24
US9464140B2 (en) 2016-10-11
RS58100B1 (sr) 2019-02-28
AU2017203087A1 (en) 2017-06-08
LTPA2019502I1 (lt) 2019-03-12
JP2018029595A (ja) 2018-03-01
LT3214091T (lt) 2018-12-10
US20140106449A1 (en) 2014-04-17
NO2019006I1 (no) 2019-02-15
JP2022002516A (ja) 2022-01-11
US8916381B1 (en) 2014-12-23
CN108103085A (zh) 2018-06-01
MY191313A (en) 2022-06-15
MY169644A (en) 2019-04-24
JP2018029594A (ja) 2018-03-01
PL3214091T3 (pl) 2019-03-29
ECSP13012739A (es) 2013-10-31
US20150118202A1 (en) 2015-04-30
EP3660029A1 (en) 2020-06-03
MA34813B1 (fr) 2014-01-02
JP2014507118A (ja) 2014-03-27
JP5947311B2 (ja) 2016-07-06
US9540445B2 (en) 2017-01-10
KR20220101745A (ko) 2022-07-19
WO2012079000A1 (en) 2012-06-14
JP6588514B2 (ja) 2019-10-09
HK1243082B (en) 2019-09-13
EP2649086A1 (en) 2013-10-16
AU2017225161B2 (en) 2019-11-21
FR19C1006I1 (enExample) 2019-04-05
HRP20182202T1 (hr) 2019-03-08
LTPA2019503I1 (lt) 2019-03-12
KR20200014343A (ko) 2020-02-10
US20160194404A1 (en) 2016-07-07
BR112013014265B8 (pt) 2023-12-19
AU2020200767A1 (en) 2020-02-27
EP3214091A1 (en) 2017-09-06
JP6293194B2 (ja) 2018-03-14
CN106220739A (zh) 2016-12-14
KR102417796B1 (ko) 2022-07-07
EA201390847A1 (ru) 2013-12-30
TR201820015T4 (tr) 2019-01-21
CY2019007I2 (el) 2019-11-27
PH12013501201A1 (en) 2013-07-29
ES2641870T3 (es) 2017-11-14
DK3214091T3 (en) 2019-01-07
HUS1900006I1 (hu) 2019-04-29
EA201790175A1 (ru) 2017-09-29
CN103492406B (zh) 2022-07-26
NZ612512A (en) 2015-03-27
LT2649086T (lt) 2017-11-10
LUC00104I1 (enExample) 2019-02-21
US8906682B2 (en) 2014-12-09
AU2022201895A1 (en) 2022-04-07
US9499629B2 (en) 2016-11-22
KR102243575B1 (ko) 2021-04-22
KR20130124521A (ko) 2013-11-14
CA2820681A1 (en) 2012-06-14
LTC2649086I2 (lt) 2020-12-28
US20150050729A1 (en) 2015-02-19
BR122021026169B1 (pt) 2023-12-12
US20150099299A1 (en) 2015-04-09
EP3214091B1 (en) 2018-10-03
AU2017225161C1 (en) 2021-07-29
DOP2013000128A (es) 2014-03-16
EP2649086B1 (en) 2017-07-19
US8975071B1 (en) 2015-03-10
KR102417796B9 (ko) 2024-03-06
MX2020005143A (es) 2020-08-17
AU2011338200A1 (en) 2013-07-04
JP7426361B2 (ja) 2024-02-01
SI3214091T1 (sl) 2019-02-28
CL2013001645A1 (es) 2014-02-14
PT3214091T (pt) 2019-01-11
FR19C1006I2 (fr) 2020-03-20
HUS1900007I1 (hu) 2019-04-29
PE20140178A1 (es) 2014-02-20
HRP20171577T1 (hr) 2017-12-01
NI201300051A (es) 2014-01-07
PL2649086T3 (pl) 2018-03-30
US9101584B2 (en) 2015-08-11
CY1119760T1 (el) 2018-06-27
MX2013006570A (es) 2013-08-26
AU2017225161A1 (en) 2017-11-09
NL300967I1 (nl) 2019-02-20
US20160159907A1 (en) 2016-06-09
US20130309258A1 (en) 2013-11-21
US20160130355A1 (en) 2016-05-12
US20130287748A1 (en) 2013-10-31
US20140370017A1 (en) 2014-12-18
ES2700966T3 (es) 2019-02-20
US9481728B2 (en) 2016-11-01
AU2011338200B2 (en) 2017-02-23
CN103492406A (zh) 2014-01-01
EA035484B1 (ru) 2020-06-23
HUE036872T2 (hu) 2018-08-28
US20160208012A1 (en) 2016-07-21
SG190997A1 (en) 2013-07-31
US20180258391A1 (en) 2018-09-13
DK2649086T3 (en) 2017-09-18
KR102243575B9 (ko) 2023-05-24

Similar Documents

Publication Publication Date Title
AU2017225161B2 (en) Use of chimeric antigen receptor-modified t cells to treat cancer
HK1243082A1 (en) Use of chimeric antigen receptor-modified t cells to treat cancer
HK40025282A (en) Use of chimeric antigen receptor-modified t cells to treat cancer
HK1185083A (en) Use of chimeric antigen receptor-modified t cells to treat cancer
HK1185083B (en) Use of chimeric antigen receptor-modified t cells to treat cancer

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: MARCELO OLIVEIRA DE SOUZA - 870240047619 - 5/6/2024